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"The best time to plant a tree was 20 years ago. The second best time is now."                
Chinese Proverb  
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Abstract 
The influenza A virus is responsible for 250,000 to 500,000 deaths every year worldwide and 
millions more could die in the event of a serious pandemic. Vaccines against influenza have 
existed for long, but until today they have been limited by extensive production times and 
reduced cross-protection between different strains of the virus. This leads to a recurrent need to 
update the vaccine composition every year, which is both costly and inadequate to fight 
pandemics. 
An innovative approach that could improve the vaccine efficacy has been recently developed 
based on the selection of conserved influenza epitopes with potential to induce broader immune 
responses. The 23-amino acid extracellular domain of the M2 protein (M2e) is highly conserved 
among different influenza A strains and thus it seems like an ideal candidate for a universal 
influenza vaccine. However, due to its small size, it is a poor immunogen when used on its own.  
The aim of this project was to produce M2e-presenting virus-like particles (VLPs) in Nicotiana 
benthamiana plants via Agrobacterium-mediated transient expression. Plants are increasingly 
being examined as alternative recombinant protein expression systems due to their safety, 
scalability and rapid production times. Moreover, numerous studies suggest the use of 
recombinant virus-like particles (VLPs) to increase the immunogenicity of antigens. Therefore, to 
obtain VLPs presenting the M2e epitope, I genetically engineered several different M2e-HA 
fusion proteins by replacing the hemagglutinin (HA) globular head and main epitope with five 
tandem repeats of M2e epitope sequences (5xM2e) from human, swine, and avian origin 
influenza A viruses. To increase the chances of obtaining VLPs, M2e-HA fusions either contained 
the HA stalk domain (5xM2e-HAstalk) or simply the transmembrane region (5xM2e-HAtrans). 
Furthermore, the tetramerizing leucine zipper derived from the General Control Protein (GCN4) 
was also included in some of the constructs to promote particle formation. In total, six different 
M2e-HA fusions were created: 5xM2e-GCN4-HAstalk, 5xM2e-GCN4-HAtrans, 5xM2e-HAstalk, 
5xM2e-HAtrans, 1xM2e-HAstalk and 1xM2e-HAtrans. The expression of these proteins was 
optimized in plants by testing different conditions and using three different expression vectors. 
Overall, I was able to show expression after only 3 days post-infiltration for most of the M2e-HA 
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fusion proteins utilizing the pEAQ-HT and pRIC 3.0 expression vectors whereas expression levels 
with pTRAc were low or non-detectable.   
Once the expression of the M2e-HA fusions was optimized, the two proteins with the highest 
potential to form VLPs were selected for further characterization (5xM2e-HAstalk and 5xM2e-
HAtrans). Using transmission electron microscopy to analyse purified proteins, both 5xM2e-
HAstalk and 5xM2e-HAtrans were shown to assemble into VLPs resembling the shape and size of 
native HA VLPs. These VLPs could also be observed in the apoplastic fractions of infiltrated leaves. 
However, due to the low number of particles observed, the successful incorporation of the M2e 
peptide on the surface of the particles was inconclusive, as shown by M2e-specific immuno-gold 
labelling experiments. Furthermore, contrarily to previous studies, co-expression of the M2e-HA 
fusions with the M1 protein resulted in a decrease in recombinant protein accumulation and VLP 
formation in our plant system. A possible inhibition mechanism by the M1 protein is discussed. 
In summary, this research provides preliminary data to produce universal influenza vaccines in 
plants. I report here for the first time that M2e fused to either the stalk or transmembrane 
domain of the HA protein, can self-assemble into VLPs without any other proteins, in N. 
benthamiana plants. Future work on the immunogenicity of the VLPs produced in this study is 
required to confirm their potential as a universal influenza vaccine that can be rapidly produced.  
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Chapter 1: Literature review 
1.1. Introduction 
Influenza is a highly infectious virus that has been causing acute respiratory illness in humans for 
thousands of years. Infections are often characterised by the sudden onset of fever, muscle pain, 
headache, and severe malaise, together with a sore throat, and nasal inflammation (Ayllon et al. 
2012). Modern historians hypothesize that the first “flu-like” disease outbreak was reported in 
412 BC by Hippocrates (Ghendon 1994). Since then, influenza viruses have caused some of the 
most devastating pandemics that humankind has ever faced. The most well-known example is 
the famous “Spanish flu” which infected about one third of the world’s population (± 500 million) 
and killed between 50-100 million people around the world during 1918 and 1919 (Johnson & 
Mueller 2002; Taubenberger & Morens 2006). The Spanish flu pandemic killed more people than 
during the First World War, and it is estimated to have reduced life expectancy in the United 
States by 10 years (Howley 2013). Influenza pandemics have been taking place randomly every 
10 to 40 years; adding up to a total of 32 (including the 2009 H1N1 “swine flu” pandemic) since 
the first influenza pandemic was documented in 1580 (Kendall 2007).  
More routinely, influenza viruses also cause smaller outbreaks called “epidemics” or “seasonal 
flu”; their cumulative burden on human societies is sometimes more devastating than pandemics 
(Cox et al. 2004). It has been estimated that each year, influenza infects about 10 - 20% of the 
total worldwide population and is responsible for 250,000 to 500,000 deaths (De Filette et al. 
2005). In the United States alone, the total economic burden of annual inﬂuenza epidemics has 
been evaluated to $87.1 billion dollars. This takes into account an average of 610,660 life-years 
lost, 3.1 million hospitalized days, and 31.4 million outpatient visits (Molinari et al. 2007).  
Nowadays, the two major strategies to fight influenza infections are with the use of antiviral 
drugs and vaccines. Antivirals can be effective but they can quickly become obsolete against 
recurrent resistant strains. Also, antivirals are typically costly (since they need to be taken daily) 
and they can only be used for therapeutic purposes. On the other hand, vaccines can be made to 
preventively combat a specific influenza strain, and vaccination is generally required only once 
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or twice for a particular strain. For these reasons, vaccination is considered the most                      
cost-effective way of controlling and preventing influenza infection (Saluja 2010).  
There are many types of flu vaccines on the market, with inactivated vaccines made of purified 
spike proteins and disrupted virus particles being the most common; however, currently every 
type of influenza vaccine only offers strain-specific immunogenicity. And so, as influenza viruses 
can very rapidly undergo unpredictable antigenic drifts/shifts, it is required to re-design vaccines 
based on varying strains for every seasonal, epidemic and pandemic immunization (Krammer et 
al. 2014).  
Apart from the lack of protection against variant strains, the use of traditional inactivated 
vaccines is also constrained by the need for specialized egg-based production facilities and long 
production times required for the creation of a new vaccine. Currently, inactivated influenza 
vaccines are made from viruses grown in the allantoic cavity of embryonated hens’ eggs. Efficient 
vaccine production in embryonated eggs requires selection of a high yield, reassorted virus strain 
that can replicate in the egg without killing it. All this makes production expensive, time-
consuming and potentially dangerous, as live viruses have to be handled (D’Aoust et al. 2010; 
D’Aoust et al. 2008). For instance, during the recent 2009 H1N1 pandemic, health authorities only 
released a candidate vaccine more than six months after the first outbreak was reported. This 
was already in the second wave of the pandemic. Luckily the 2009 pandemic turned out to be 
only of mild severity with a low case-fatality rate. However, it is clear that an alternative to 
current vaccines needs to be found.  
Emerging and re-emerging influenza A infections in humans and animals have been reported with 
increased frequency in recent years (Morens et al. 2004). The threat of highly virulent avian 
influenza, such as H5N1 and swine-origin H1N1 viruses, emphasizes an urgent need to develop a 
universal influenza vaccine, which could provide cross-protection against different influenza virus 
strains, and longer-lasting and more universal protection.  
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1.2. Classification and structure 
1.2.1. Classification 
Influenza A viruses belong to the Orthomyxoviridae family which according to the International 
Committee on Taxonomy of Viruses (ICTV), consists of six genera: these are Influenzavirus A, 
Influenzavirus B, Influenzavirus C, Isavirus, Thogotovirus, and the recently added Quaranjavirus 
(International Committee on Taxonomy of Viruses 2014). All of the Orthomyxoviridae viruses 
have segmented single-stranded negative sense RNA genomes. However only viruses in the 
Influenzavirus genera are known to infect humans; with the exception of a few reported cases of 
thogotovirus human infections (Kosoy et al. 2015; Butenko et al. 1987). Despite being able to 
infect humans, the three types of influenza viruses are significantly different from each other; 
such differences include (but are not limited to): the number of RNA segments, pathogenicity, 
antigenic differences in the major internal proteins of the virus, morphological features, protein-
encoding mechanisms, and host range infectivity (Knipe 2001). 
Influenza B and C viruses were first isolated in 1940 and 1949 respectively (Francis 1940; Taylor 
1949). Both of these viruses normally only infect humans, but there have been some reports of 
influenza B isolated from seals and influenza C from pigs and dogs (Osterhaus et al. 2000; Guo et 
al. 1983). Type A influenza viruses, on the other hand, have a natural host in aquatic birds, and 
can infect a wide variety of mammals including humans, horses, swine, domestic and wild birds 
and other mammals (Suarez & Schultz-Cherry 2000). All influenza A types can infect birds, with 
the exception of the two newly discovered subtypes H17N10 and H18N11 which have only been 
found in bats (Wu et al. 2014). Only types A and B cause human disease of any concern, with type 
A being responsible for every pandemic and most epidemics (Deng et al. 2015). Accordingly, only 
the type A will be discussed in detail in this review.  
The influenza A virus was first isolated from humans in 1933 by Wilson Smith, Sir Christopher 
Andrewes, and Sir Patrick Laidlaw at the National Institute for Medical Research (NIMR) outside 
of London. They showed that the virus could infect ferrets and used them to propagate the virus 
in the laboratory (Smith et al. 1933). It was only in 1975 that the virus was first successfully 
maintained in MDCK cells after the discovery that the addition of trypsin to culture media was 
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necessary (Tobita et al. 1975). Since then, influenza A has been one of the most studied human 
viruses in the last century.  
The nomenclature given to different influenza strains is done firstly according to their genus 
(type), the species from which the virus was isolated (except for humans), location of the isolate, 
the number of the isolate, the year of isolation, and, for influenza A viruses, the haemagglutinin 
(H) and neuraminidase (N) subtypes is given in parentheses at the end. For example, 
A/Vietnam/1194/2004 (H5N1), is the 1194th isolate of an H5N1 subtype virus isolated from 
humans in Vietnam in 2004. According to the US Centers for Disease Control and Prevention 
(CDC) there are currently 18 different haemagglutinin (H1 to H18) subtypes and 11 different 
neuraminidase (N1 to N11) subtypes for influenza A viruses (CDC, 2013). 
1.2.2. Structure 
The influenza A virion has a pleomorphic shape: it is typically spherical or elliptical (Figure 1A), 
ranging from 80-120 nm in diameter but it can occasionally be filamentous (Figure 1B), reaching 
more than 20 μm in length. Surprisingly, most laboratory-adapted strains of influenza A virus are 
primarily spherical or elliptical, whereas clinical isolates are generally filamentous and their 
Figure 1| Different shapes of influenza A virions captured by Transmission Electron Microscopy.              
A) Spherical and eliptical-shaped virions from the strain [A/WSN/33 (H1N1)]. B) Filamentous-shaped 
virions from [A/Udorn/307/72 (H3N2)]. C) Irregular-shaped virions from [A/Puerto Rico/8/34 (H1N1)]. 
Bars represent 200nm (Noda 2012). 
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adaptation in eggs results in the loss of this filamentous phenotype (Noda 2012). The significance 
of the filamentous morphology for virus replication and pathogenesis remains unclear, but it is 
thought to be a genetic trait that is essential for virus survival in nature. There have also been 
reports of influenza virions with irregular shapes (Figure 1C), but this has been associated with 
artefacts introduced during sample preparation procedures that involve ultracentrifugation and 
storage (Almeida & Waterson 1967; Stevenson & Biddle 1966). 
Besides its complex shape, influenza A virions possess a lipid envelope that is derived from the 
host plasma membrane during budding. From this membrane, two surface glycoproteins bulge 
out: the rod-shaped haemagglutinin (HA) assembled in trimers, and tetramers of the mushroom-
shaped neuraminidase (NA) (Figure 2). These surface proteins form 10-14nm “spikes” on the 
surface of the virion, which are readily observable using negative stain electron microscopy. It is 
estimated that there are four HA subunits for each NA (Howley 2013). Embedded within the 
membrane is the relatively small matrix protein 2 (M2), whilst the matrix protein 1 (M1) is 
underneath the envelope.  Within the matrix lies the influenza A segmented genome: eight 
negative-sense RNA strands, each wrapped up into a rod-shaped, double-helical 
ribonucleoprotein complex (RNP). Each RNP can be between 30-110nm (corresponding with the 
size of its associating vRNA) and contains a viral RNA bound to multiple copies of the nucleocapsid 
Neuraminidase 
(NA) 
Haemagglutinin 
(HA) 
Matrix protein 
(M1) 
Lipid envelope 
vRNP 
Ion channel 
(M2) 
Figure 2| Schematics of influenza A virion structure. HA, NA and M2 are the outer envelope proteins. 
M1 forms the core of the virion which protects the genomic material: eight negative-sense RNA strands, 
each wrapped up into a viral ribonucleoprotein complex (vRNP). Adapted from the CDC webpage - 
http://www.cdc.gov/flu/images.htm. 
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protein (NP) and the heterotrimeric viral polymerase, consisting of PA, PB1, and PB2 proteins 
(Zheng & Tao 2013). The estimated composition of influenza virus particles is about 1% RNA, 5% 
to 8% carbohydrate, 20% lipid, and approximately 70% protein (Howley 2013). 
1.2. Replication 
Influenza virus attachment to the cell host is mediated by the specific binding of the HA spikes to 
sialic acid residues present on host cell surface glycoproteins or glycolipids. Two major linkages 
exist between sialic acids and the carbohydrates they are bound to: these are α(2,3) and α(2,6). 
Epithelial cells in the human trachea have predominantly the α(2,6) linkage whereas gut epithelial 
cells from ducks have the α(2,3) linkage (Knipe 2001). Receptor specificity to sialic acid linkages 
is thought to be an important determinant of host range (Cox & Subbarao 2000). In agreement 
with this is that human influenza viruses preferably bind to sialic acids with an α(2,6) linkage, 
whereas avian and equine influenza viruses bind to an α(2,3) linkage (Knipe 2001). There have 
been relatively few reports of direct natural human infections with avian influenza, with the 
notable exceptions of the 1997 and 2004 Hong Kong H5N1 outbreaks and continuing sporadic 
transmissions of H5N1 in several countries worldwide (Kandun et al. 2006; Chan 2002; Tran et al. 
2004; Beigel et al. 2005; Gao et al. 2013; Butt et al. 2005).  
Exceptionally, the trachea of pigs possesses both sialic acid linkages, making them susceptible to 
both avian and human influenza (Naffakh & van der Werf 2009; Brown 2000; Hass et al. 2011; 
Ma et al. 2008). Because of the segmented nature of the influenza genome, pigs that are infected 
with both avian and human influenza viruses can be seen as “mixing vessels” for avian and human 
influenza viruses to exchange or reassort whole fragments of their genome; thus, giving rise to 
novel influenza strains. This event is called “antigenic shift” and it can potentially result in the 
production of new dangerous pathogenic viruses by introducing a new HA or NA from another 
subtype, one that had not circulated in humans for a long time or even one that had never 
circulated in humans before. The most recent example of this, was the appearance of the 
reassortant 2009 H1N1 pandemic strain known as “swine flu”. This strain of influenza contained 
three classical swine genes (HA, NP, and NS1), one human gene (PB1), two North American  
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1918-19 
H1N1 
“Spanish 
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H2N2 
“Asian 
1968-69 
H3N2 
“Hong Kong 
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2009 
H1N1 
“Swine flu” 
? 
Figure 3| A) Origin of the Swine Influenza H1N1pdm 2009 strain. Blue circles represent complete 
influenza A virus genomes; grey lines are genes that remained unchanged; yellow lines are genes that 
reassorted but did not end up into the 2009 H1N1 strains; red lines show origins of specific genetic 
components. Reprinted with permission from Prof. Ed Rybicki. Copyright (Rybicki & Kightley 2015).                                              
B) Influenza A pandemics of the 20th century. 
A) 
B) 
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avian genes (PB2 and PA), and two Eurasian avian-like swine genes (N1 and M1) (Figure 3A); it 
was unrelated to the human seasonal H1N1 viruses that have been in general circulation among 
people since 1977 (del Rio & Guarner 2010; Rybicki & Kightley 2015).   
Since the beginning of the 20th century there have been five major antigenic shifts that resulted 
in viruses that caused pandemics (Figure 3B): in 1918 the appearance of H1N1 started the 
“Spanish Influenza”; in 1957, the H1N1 subtype was replaced with H2N2, which caused the “Asian 
Influenza”; in 1968 the H2N2 replacement with H3N2 led to the beginning of the “Hong Kong 
Influenza”, in 1977 the H1N1 reappeared in Russia thus starting the “Russian Influenza” and 
finally the “Swine Flu” in 2009 with the new triple reassortant H1N1, antigenically distinct from 
previous strains, that caused a mild pandemic and largely replaced previous seasonal H1N1 
viruses in the human population (Kilbourne 2006; Taubenberger 2006; Brown 2000; Lagacé-
Wiens et al. 2010). It is important to note that these shifts occurred sporadically and after 
irregular periods of time, making predictions for the next shift effectively impossible. It has 
further been postulated that pigs could even act as reservoirs for avian influenza, allowing them 
to slowly adapt to humans without the need of reassortment (Ito et al. 1998). 
Besides the ability to easily reassort with other subtypes, the influenza virus is also incredibly 
susceptible to mutations in its genome. This is because the influenza RNA-dependent RNA 
polymerase lacks proofreading, resulting in replication errors at a rate of about one in every 104 
bases (Holland et al. 1982). Given that the influenza A genome is about 13.6 kb long, this equals 
to about 1 base pair mutation per genome (Holland et al. 1982). Not surprisingly, most of these 
mutations are not viable and end up killing the virus. However sometimes, key mutations in the 
antigenic regions of the HA or NA proteins allow the virus to escape antibody neutralization and 
even create anti-viral drug resistance (as explained in the next section) (Wilson et al. 1981; 
Samson et al. 2013; Hayden & de Jong 2011; Rambaut et al. 2008; Scholtissek et al. 1993). These 
mutations typically cause epidemics that can prevail for 1 to 5 years before being replaced by a 
different variant (Howley 2013). More importantly, other than mutations in the antigenic regions, 
mutations in functional regions can drastically increase the pathogenicity of the virus. 
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For example, upon binding to the sialic acid residues, the HA precursor must be cleaved for 
endocytosis to occur. In its precursor conformation, the HA molecule is named HA0. HA0 is made 
up of two subunits linked by disulfide bonds: HA1, which contains the sialic acid receptor binding 
domain, and HA2, which contains the fusion peptide. For viral activation and internalization, HA0 
must be cleaved by a trypsin-like serine endoprotease at the specific cleavage site, between the 
HA1 and HA2 domains of the protein. In mammals like humans and swine, this specific protease 
is only expressed in the epithelial cells of the upper and lower respiratory tract, which restricts 
the replication of the virus to those areas. On the other hand, in aquatic birds normal influenza 
replication takes place in the intestinal tract, because it is the only location where the protease 
is produced. In both cases these are considered to be “normal” regions for influenza replication, 
and usually only cause mild symptoms. 
However, in some cases, influenza viruses can undergo mutational changes in the HA cleavage 
site, thus making them able to be cleaved by ubiquitous cellular proteases. Consequently, the 
virus can then replicate in different organs including the spleen, liver, lungs, kidneys, and brain, 
making it highly pathogenic. This is the case for some of the H5 and H7 HA proteins that have 
multiple basic amino acid residues at the HA1-HA2 cleavage site. Any type of mutation in the 
influenza genome that affects immunogenic proteins is commonly called “antigenic drift”. 
1.3. Influenza treatments 
1.3.1. Antiviral drugs 
At present, there are two classes of drugs approved and on the market against influenza, the 
adamantanes and the neuraminidase inhibitors.  
The two adamantane derivatives in use for influenza treatment since the mid-to-late 1960s are 
amantadine and rimantadine (Kato & Eggers 1969). These drugs are effective against all subtypes 
of influenza A virus, but not against influenza B or C viruses (Howley 2013). They work by 
specifically targeting and blocking the proton channel formed by the influenza A virus M2 protein, 
thereby inhibiting the acidification of the virion interior and thus, viral uncoating. Treatment of 
most influenza A strains with amantadine or rimantadine results in symptomatic improvements, 
including accelerated clearance of local symptoms and fever; the overall duration of illness is 
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estimated to be reduced by about 1.5 - 2.5 days (Stiver 2003). Until 2004, the proportion of 
resistance to adamantane-derived dugs among seasonal influenza viruses remained low. 
However, during the 2003 to 2004 season, the rate of resistance in seasonal H3N2 viruses 
increased to 12.3% and one year later more than 90% of all H3N2 viruses were resistant to 
adamantane compounds. This is typically attributed to a S31N point mutation in the M2 gene 
that makes the virus resistant to both adamantane drugs (Wathen et al. 2013; Nelson et al. 2009). 
Nowadays, most circulating human H3N2 viruses, the 2009 swine-origin H1N1 pandemic virus, 
and some highly pathogenic avian H5N1 influenza viruses are resistant to ion channel inhibitors 
(Govorkova et al. 2013; Malik Peiris et al. 2009; Bright et al. 2006; Bright et al. 2005). In fact, 
resistance to amantadine and rimantadine is so frequent that most health authorities worldwide 
recommended that neither be used anymore for the treatment and prevention of influenza A 
infections (WHO 2015; Walaza & Cohen 2015). This situation has resulted in a heavy reliance on 
the neuraminidase inhibitors. 
Neuraminidase inhibitors were only approved in the late 90’s and are mainly composed of two 
drugs: oseltamivir (Tamiflu®) and zanamivir (Relenza®). Like the name indicates, these drugs act 
by targeting the neuraminidase protein. However, contrarily to ion channel inhibitors that act in 
the early stages of replication, NA inhibitors have an effect towards the end of the replication 
cycle. They bind to the NA protein of the virus and inhibit the budding viruses from being released 
from cellular surfaces. If treatment is started early they can statistically reduce symptoms, the 
duration of illness and the amount of virus shed; however, treatment later in infection may still 
be beneficial (Jefferson et al. 2009; Monto et al. 1999; Laver et al. 1999; Louie et al. 2010). Drug 
resistant mutant strains are less common than those seen with the ion channel inhibitors, but 
have been reported (Hurt et al. 2009; Baranovich et al. 2010; Sheu et al. 2008). Nevertheless, NA 
inhibitors are recommended by the WHO as the primary treatment for human HPAI H5N1 virus 
infections (WHO 2015).  
In conclusion, antiviral drugs can be efficiently used for treatment to potentially shorten the 
duration and decrease the severity of influenza infections. They can also be a useful tool in the 
early stages of a new outbreak when vaccines are not available. However, due to the increased 
appearance of mutant resistant strains, their use for chemoprophylaxis is currently not 
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recommended by the WHO (Walaza & Cohen 2015). Even though additional antiviral drugs with 
novel mechanisms of action are currently being tested, vaccination remains the solely accepted 
method to prevent influenza infections (Shaw 2011; Darwish et al. 2011). 
1.3.2. Current vaccines 
Vaccination is the most cost-effective means to prevent influenza virus infections and 
complications. It can significantly reduce and lessen the symptoms associated with influenza 
disease, especially for groups at risk including young children and the elderly. During the            
2012 - 13 period, the CDC estimates that in the USA 42.4 million people were vaccinated against 
influenza, which prevented an estimated 6.6 million illnesses, 3.2 million medically attended 
illnesses, and 79,260 hospitalizations (Centers for Disease Control and Prevention (CDC) 2013).  
There are three different classes of vaccines that have been licensed against seasonal influenza, 
which are inactivated, live attenuated, and recombinant HA vaccines (Centers for Disease Control 
and Prevention (CDC), 2013). All three vaccine types focus on the production of neutralizing 
antibodies against the HA protein and in some cases against the NA protein as well, to neutralize 
the virus and prevent infection (Gerhard 2001). These vaccines are generally trivalent, containing 
H1N1 and H3N2 subtypes of influenza A along with the predicted dominant lineage of influenza 
B (Belshe et al. 1998; Houser & Subbarao 2015). Recently, several quadrivalent formulations 
containing two distinct lineages of influenza B have been licensed and are also currently on the 
market (Traynor 2012). 
Inactivated vaccines 
Inactivated influenza vaccines (IIVs) are generally produced by propagation of the virus in the 
allantoic fluid of embryonated hens’ eggs and then purifying and concentrating it by zonal 
centrifugation or column chromatography. The first influenza inactivated vaccines administered 
to humans consisted of whole-inactivated virus treated with either formalin or β-propiolactone 
for inactivation (Logrippo 1960). However, even though whole virus vaccines were shown to be 
highly immunogenic, they were later correlated with severe reactogenicity and adverse effects 
among the vaccinated, and so are no longer widely used (Gross et al. 1977). To reduce adverse 
reactions, vaccine virus preparations are now further disrupted by treatment with a nonionic 
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detergent (for example, Triton X-100) to make so-called “split vaccines” which may be partially 
purified by ultracentrifugation (subunit vaccines) to remove viral ribonucleoprotein complexes. 
The end product for subunit vaccines is composed of membrane vesicles that mostly contain the 
HA glycoprotein. 
The amount of immune-reactive HA recommended by the Advisory Committee on Immunization 
Practices to confer protection for adults and older children is 15 µg of each purified HA protein 
administered intramuscularly, or 9 µg of each purified HA protein administered intradermally 
(Center for Disease Control and Prevention (CDC) 2013). This dose is approximately equivalent to 
the amount of purified virus obtained from the allantoic fluid of one to three infected 
embryonated eggs, depending on the strain of the virus. A higher dose of 60 µg for each HA is 
also available for the elderly population aged 65 years and older to increase immunogenicity 
(DiazGranados et al. 2014).  
While inactivated vaccines do elicit strong type-specific antibody responses dominated by 
circulating IgG against the HA and NA proteins, they have been shown to induce poor levels of 
mucosal IgA antibody and cell-mediated immune responses (Cox et al. 2004; Blazevic et al. 2000).  
The degree of protection conferred by inactivated vaccines is highly dependent on the age of the 
vaccinee and his or her history of influenza, and also on the antigenic match between the vaccine 
strains and those circulating in the population (Cox et al. 2004). Overall, IVs are 50 - 90% effective 
among young adults and children, but have lower efficacy in elderly populations (Jackson et al. 
2010; Goodwin et al. 2006; DiazGranados et al. 2012; Jefferson et al. 2005; Osterholm et al. 2012; 
Cox et al. 2004)  
Live-attenuated vaccines 
The second type of licensed influenza vaccine is the live attenuated influenza vaccine (LAIV). 
Current approved LAIV vaccines are all quadrivalent, and composed of live, cold-adapted 
attenuated viruses. LAIV were developed by several passages of a wild-type virus at progressively 
lower temperatures in primary chicken kidney cell cultures and embryonated eggs. This approach 
results in cold-adapted, temperature-sensitive, and highly attenuated master donor strains with 
low infectivity in humans. In the United States, the two master donor strains used are the A/Ann 
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Arbor/6/60 and B/Ann Arbor/1/66, while in Eastern Europe (first approved LAIV vaccines), the 
two strains used are the A/Leningrad/134/17/57 and B/USSR/60/69 (Howley 2013; Shcherbik et 
al. 2016). These mutant donor strains differ by only seven or eight amino acids from the 
respective wild-type viruses. Although it has never happened, it is theoretically possible that they 
could undergo genetic reversion into a pathogenic, transmissible influenza strain (Soema et al. 
2015; Cox et al. 2004).  
Seed viruses for vaccine production are generated by combining, via reassortment or reverse 
genetics, the six internal segments from the master donor strains, with the HA and NA surface 
proteins from the strain against which vaccination is desired (Snyder et al. 1988; Maassab & 
Bryant 1999). These are referred to as 6/2 cold reassortant vaccines, and as for IIVs, they are also 
produced in embryonated hens’ eggs. However, unlike IIVs, LAIVs are administered intranasally 
by spray. This results in limited viral replication in the upper and lower respiratory tract of the 
recipient. Shedding of live attenuated viruses on days 1 to 2 post-vaccination is frequent in young 
children and has been shown to sometimes cause wheezing in infants under 2 years old (Belshe 
et al. 2007). For these reasons, LAIVs are generally not recommended for children under 2 years 
of age, the elderly, and those caring for people with high risk of severe influenza infection. In the 
US and Canada, LAIVs are approved only for children and adults between the age of 2 to 49 and 
59 respectively; whereas in Europe regulations restrict the vaccine to children of 2 to 18 years of 
age (Sridhar et al. 2015).  
In contrast to IIVs, LAIVs induce a longer-lasting, broader immune response (humoral and 
cellular) with induction of neutralizing antibodies, local IgA and antigen-specific                      
cytokine-secreting T-cells (Sridhar et al. 2015). Meta-analyses have shown that LAIV are generally 
more efficacious in children when compared to IIVs (Belshe et al. 2007; Jefferson et al. 2008; 
Jefferson et al. 2012; Howley 2013; Osterholm et al. 2012). This can in most part be explained by 
the fact that LAIVs mimic a more natural influenza infection. 
Recombinant vaccines 
In 2013, the FDA announced the approval of the first (and to date, the only) licensed recombinant 
influenza vaccine, FluBlok®. FluBlok® is produced in an insect cell expression system and is 
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composed of three full-length HA proteins derived from the WHO recommended strains. This 
vaccine has a three-fold higher total protein content (45 µg for each subtype) than inactivated 
virus vaccines (Yang 2013). Although FluBlok® has demonstrated a significant immunogenic 
capacity in young and older adults, its efficacy in children and the elderly has not yet been 
completely evaluated (Cox et al. 2015). Therefore, FluBlok® is only recommended for people 
between 18-49 years of age (Houser & Subbarao 2015).  
One great advantage that FluBlok® has compared to IIVs and LAIVs, is that it is not produced in 
eggs: this allows people with egg allergies to be vaccinated safely. Also, production steps can be 
achieved in shorter periods of time because they are not dependent on an egg supply, limited by 
the selection of viruses that are adapted for growth in eggs, and additionally do not require high-
level biocontainment facilities since production is based on recombinant technology (cloning and 
expression of recombinant proteins). All this can be extremely useful in the event of a pandemic 
or vaccine supply shortage.  
Main disadvantage of current vaccines 
Despite the fact that influenza vaccines have been developed and tested since the late 1930s, 
several limitations still exist involving both their availability and their effectiveness (Stokes et al. 
1937).  
One clear limitation that all current licensed vaccines have, with the exception of FluBlok®, is that 
they are produced in eggs. Egg-based production can take up to 8 months to produce a functional 
vaccine, and is critically dependent on continuous supply of expensive fertilized eggs - which 
would certainly be limited in case of a pandemic (Wong & Webby 2013). Moreover, egg-based 
vaccine facilities need to be under strict sterile conditions because eggs are highly susceptible to 
avian or microbial contaminants which could jeopardize vaccine supplies. This was observed 
during 2004 - 05, when one of the major manufacturers of egg-based vaccine in the US, Chiron 
(Emeryville, CA, US), announced that none of its trivalent inactivated influenza vaccine (TIV) 
would be available for distribution because of bacterial contamination; this caused major 
shortages in the vaccine supply (McQuillan et al., 2009).  Furthermore, there is a possibility that 
unregulated levels of egg protein contaminants in the vaccines could cause anaphylactic 
15 
 
responses in egg-allergic individuals (Goldis, Bardina, Lin, & Sampson, 2010). Finally, in a time 
where research is heading towards universal vaccines made from recombinant protein 
expression, it is simply unfeasible and unpractical to use eggs to produce these molecules when 
there are many other more modern and productive systems that have been extensively used for 
similar purposes. 
Another limitation of current vaccines, concerns using HA and NA antigens to elicit immune 
responses. As it was seen previously, the HA and NA genes are highly susceptible to antigenic 
shifts and drifts; this results in current vaccines requiring bi-annual revision and reformulation of 
their antigenic content (once for each influenza season of the northern and southern 
hemisphere). For this, the WHO has to conduct several surveillance studies on the immune status 
of the populations and on antigenic information about circulating viruses, before recommending 
a predicted vaccine composition for the upcoming season’s vaccine (Ampofo et al. 2012). Since 
this decision must take place 7 to 8 months in advance of ‘‘flu season’’ to accommodate the steps 
of vaccine production, the predicted vaccine strains have a high chance of differing from the 
actual viruses circulating during the subsequent influenza season. Between 1999 and 2009, there 
were four vaccine compositions selected by the WHO for application in the northern hemisphere 
that failed to effectively match the epidemic strain because a new antigenic variant emerged 
after the vaccine formulation decision was made (Jackson 2009). It is estimated that these 
mismatches occur at a similar frequency in the southern hemisphere (Richard et al. 2010).  
Not surprisingly, vaccine mismatches can result in suboptimal vaccine efficacy. A meta-analysis 
study of healthy young adults has shown that vaccine efficacy against influenza was 80% (95% CI 
56 - 91%) during years with a good match versus 50% (95% CI 27 - 65%) during years with a poor 
antigenic match (Jefferson et al. 2007). Another analysis has also found from a 10 - year 
observational study of influenza vaccine effectiveness in community-dwelling elderly persons, 
that vaccine effectiveness dropped to 37% (95% CI 31 - 43%) during poor match seasons versus 
52% (95% CI 49 - 54%) during good match seasons (Nichol et al. 2007). 
Moreover, as it was discussed previously, it is nearly impossible to predict antigenic shifts that 
will cause pandemic-size infections. With the current egg-based technology, it would take around 
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5-6 months before a vaccine based on a new influenza strain can be produced on a large scale. 
This was clearly demonstrated during the 2009 H1N1 pandemic, where vaccine production and 
distribution organizations were not rapid enough to prevent the second wave of the pandemic 
(Broadbent & Subbarao 2011). Moreover, considering the current world egg-based 
manufacturing capacity estimated at 1,420 million doses, it seems that this system is not feasible 
for worldwide vaccine distribution (Partridge & Kieny 2013).   
Even though it is well-known that influenza A virus is highly susceptible to mutations in its 
genome, especially on the antigenic segments of the HA and NA protein, every single influenza 
vaccine currently on the market is still designed primarily to elicit an immune response to these 
same main antigenic segments of the HA and NA proteins. This poses an obvious short-fall in the 
way current vaccines are being designed that leads to many different problems. After the 2009 
pandemic, and with the increase in sporadic zoonotic avian influenza infections in humans with 
pandemic properties, researchers are moving towards new “universal” vaccines that induce 
broader cross-protection against a wide range of strains compared to currently licensed vaccines.  
1.4. Future vaccines 
From previous experiences with influenza epidemics and pandemics, the efficacy of current 
commercialized vaccines has become a topic of debate (Osterholm et al. 2012). Health 
authorities are finally realizing that next-generation influenza virus vaccines are urgently needed. 
Novel approaches to current vaccination against influenza have been focusing on two major 
improvements:  
 inducing more broadly cross-protective immune responses (universal vaccines) 
 decreasing the time of production of vaccines (other manufacturing methods) 
In the next section, I will address the prospects and challenges of these two key points. 
1.4.1. Universal vaccines 
An ideal universal influenza A vaccine would not only have to induce a robust protective immunity 
against intrasubtypic drift variants, but also against various subtypes of influenza A virus, 
including those that have pandemic potential. This vaccine would not need to be administered 
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or updated every year and it would buy time in a pandemic scenario by reducing 
morbidity/mortality until a tailor-made vaccine would become accessible (de Vries et al. 2015). 
To produce universal vaccines, researchers have been targeting conserved epitopes that exist 
across different influenza virus subtypes and trying to make them sufficiently immunogenic to 
induce protective immunity. Although influenza has a wide variety of conserved sequences, most 
of these are located on the internal proteins and the mechanism of protection conferred by these 
proteins remains unclear or is not considered significant (Staneková & Varečková 2010; Wiersma 
et al. 2015). On the other hand, the stalk domain of the HA and the extracellular domain of the 
matrix protein 2 have been extensively studied and are considered the most promising conserved 
targets for a universal influenza vaccine.  
HA stalk domain 
The HA protein is the largest and most abundant envelope protein of the influenza virion. During 
viral replication, HA is first synthesized as a single precursor (HA0) that then undergoes 
trimerization and post-translational modifications via the ER and the Golgi apparatus before 
being transferred to the cell surface. Once it is exported to the cell surface, HA0 is cleaved by 
cellular host proteases into HA1 and HA2 which remain cross-linked by a disulfide bond.  
The HA comprises two distinct domains: these are the globular head domain and the stalk domain 
(Figure 4). The former is situated entirely in HA1 and contains the sialic acid receptors necessary 
for virus binding to host cells. Due to its size and position, most virus-neutralizing antibodies are 
directed against this region, making it highly immunogenic. The stalk domain is located in both 
HA1 and HA2. It is situated proximal to the membrane region and forms a stem-like structure 
that mediates the essential fusion of viral and endosomal membranes once the virus is taken up 
into the cell (Jang & Seong 2014; Howley 2013).   
Although the HA molecule is highly susceptible to antigenic drift, the stalk domain presents 
relatively more highly conserved regions (48 - 85% homology between subtypes) (Table 1) 
compared to the globular head (34 - 59% homology between subtypes) (Gerhard et al. 2006); 
presumably because neutralizing antibodies are primarily targeted against the globular head in 
natural infection, thus building evolutionary pressure for mutations in this region. For this reason, 
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researchers have been focusing on the stalk domain as a candidate for a universal influenza 
vaccine.  
Broadly neutralizing antibodies directed against the stalk domain can be found in people after 
vaccines or after virus infections (Miller et al. 2013; Krammer et al. 2012; Nachbagauer et al. 
2014; Throsby et al. 2008). These antibodies have a broad inhibitory spectrum and bind to highly 
conserved epitopes in diverse influenza viruses from Group 1 (H1, H2, H5, H6, H8, H9, H11, H12, 
H13, and H16), Group 2 (H3, H4, H7, H10, H14, and H15), or both groups of the HA protein 
(Hashem 2015; Krammer & Palese 2013; Wong & Webby 2013). In contrast to antibodies directed 
against the globular head, which act by obstructing the binding of the virus to the host cells, stalk-
directed antibodies are thought to reduce influenza virus replication by inhibiting the fusion of 
viral and endosomal membranes (Edwards & Dimmock 2000). In theory, antibodies would bind 
to the stalk domain outside of the cell, enabling them to be endocytosed together with the virus 
(Krammer et al. 2014); this then either prevents the conformational change of HA during 
acidification of the endosome (Imai et al. 1998; Brandenburg et al. 2013), or blocks the insertion 
of fusion peptide into the endosomal membrane (Varecková et al. 2003).  
However, these antibodies are produced in quantities that are not significant because of the 
bulky and highly immunogenic globular head domain that gives limited access to the stem, and 
is frequently immune-dominant.  To try directing the immune response primarily to the stem 
region, vaccine experts have designed various vaccination strategies in which the HA globular 
Table 1| Percent identity comparison between the stalk domains of HA from different strains. Sequences 
were obtained from Genbank and alignement was performed using the CLCBio software (Qiagen). 
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head domain has been removed. The first true success using headless HA happened with 
vaccination of mice with a mammalian expressed virus-like particle (VLP) composed of HIV Gag 
protein fused to headless HA construct based on the A/Puerto Rico/8/34 (H1N1) HA. These VLPs 
generated antisera that were cross-reactive against multiple subtypes of haemagglutinin and 
protected against lethal influenza virus challenges (Steel et al. 2010). Another group then 
obtained the same results using an E. coli produced truncated HA2 protein, although it 
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demonstrated a lessen breadth of reactivity compared to the VLPs (Bommakanti et al. 2010). 
More recently, there have been several studies that show successful homologous and/or 
heterosubtypic protection after vaccination with different headless HA (Mallajosyula et al. 2014; 
Impagliazzo et al. 2015; Wohlbold et al. 2015; Yassine et al. 2015).   
An alternative strategy to induce stalk-specific immunity is to repeatedly vaccinate with 
chimaeric HA proteins that have the same stalk domain but a variable globular head region. The 
reasoning for this is that with each vaccination, the immune response against the stalk domain is 
boosted, whereas the response to the globular region remains a primary response. This approach 
has been demonstrated by Krammer et al. (2013) where, either H1 or H3 stalk domains were 
combined with several different globular heads and used for sequential vaccinations in mice and 
ferrets. They found that these vaccinations induced high titres of stalk reactive antibodies and 
protected both animal types against homologous and heterotypic challenges including lethal 
H5N1 challenges (Krammer et al. 2013). These approaches show considerable potential for 
including the HA stalk domain in a universal influenza vaccine candidate. 
Extracellular domain of matrix protein 2 
Although the HA stalk domain has great prospects as a universal vaccine, perhaps the most 
explored universal influenza vaccine candidate remains the extracellular domain of the M2 
protein (M2e). M2 is a small transmembrane protein that forms tetramers and functions as a                        
pH-dependent proton channel. It regulates the pH inside the virion core, which is essential for 
virus maturation and uptake into the host cell (Gerhard et al., 2006). It is the smallest protein of 
influenza virus being only 97 amino acids long and its structure can be divided into three parts 
(Figure 5): the extracellular N-terminal domain (M2e, positions 2 - 24), the transmembrane (TM) 
domain (positions 25 - 46) and the intracellular C-terminal cytoplasmic domain (positions 47 - 97) 
(Deng et al. 2015). M2 tetramers can be found in the plasma membrane of infected cells in large 
numbers, with an approximate ratio of two M2 tetramers for each HA trimer in CV-1 cells (Lamb 
et al. 1985); however, only a few copies get incorporated into the envelope of mature virions 
(ratio of 1:10 - 100 M2:HA) (Zebedee & Lamb 1988).  
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In the late 1980s-90s, several groups demonstrated for the first time that anti-M2 immunity 
responses could confer protection and inhibit homologous and heterologous virus replication 
both in vitro and in vivo models (Zebedee & Lamb 1988; Treanor et al. 1990; Slepushkin et al. 
1995). The mechanisms of the immune responses induced by M2 remain to this day unclear and 
require future studies. Presumably, protection is conferred by anti-M2 IgG antibodies, which, 
contrarily to neutralizing antibodies elicited by seasonal vaccines, reduce virus replication by 
binding to infected cells (higher amounts of M2 compared to virions) and mediating antibody 
dependent cell-mediated cytotoxicity (ADCC) and antibody dependent cell-mediated 
phagocytosis (ADCP) (Deng et al. 2015). 
M2e TM CT N - - C 
Viral membrane 
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out 
Figure 5| Three-dimensional structure and schematic representation of the influenza M2 protein. 
A) Lateral view of the M2 tetramer in context of the viral membrane. The M2 structure was produced 
using JSmol, on basis of the file from the Protein Data Bank, code 2L0J. B) Schematic representation 
of the M2 primary structure. M2e: extracellular domain, TM: transmembrane domain,                               
CT: cytoplasmic domain.  
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The interest in using the M2 protein to produce a universal vaccine comes from its extracellular 
domain M2e. In multiple sequence alignments, M2e has been shown to be incredibly conserved 
among different influenza strains, especially for human strains (Fiers et al. 2004). For example, 
residues 2-9 (SLLTEVET) of M2e were found to be 100% conserved among human influenza A 
isolates and approximately over 99% among all influenza A subtypes (Liu et al. 2005). This high 
level of conservation can be attributed to the lack of selective pressure caused by the low 
incorporation levels of M2 molecules into the virion and steric hindrance from the much larger 
HA and NA surface proteins (Rappazzo et al. 2016).  
These two factors also result in low levels of immunity against the M2 protein. Studies have 
shown that natural virus infections or vaccination with current vaccines induce weak immune 
responses against the M2e fragment (Feng et al. 2006). Presumably, most immunogenic bodies 
generated in the course of natural infection are directed to HA and NA, making the frequency of 
M2e-specific precursor B cells lower than those of HA- and NA-specific B cells (Gerhard et al. 
2006). Hence, to produce an effective vaccine, researchers have developed a plethora of different 
methods to enhance anti-M2e immune responses.  
One very efficient way to make M2e immunogenic is by presenting it on the surface of VLPs by 
chemically or genetically fusing it to a variety of carriers that form VLPs. VLPs are composed of 
structural viral proteins that can self-assemble to make multiprotein particle structures 
resembling the morphology of live virions. VLPs allow for the presentation of desired epitopes in 
a ordered way, which has been shown to increase immune responses (Bachmann et al. 1993). 
This technique was first adopted for influenza in an early study by Neirynck et al. (1999), where 
M2e was genetically fused to the hepatitis B virus core protein. When expressed in E. coli, the 
M2e-HBc fusion would “spontaneously associate to form VLPs” because of the HBc backbone. 
These VLPs elicited high levels of anti-M2e IgG antibodies and conferred broad protection in mice 
against challenge with H1N1 and H3N2 viruses; passive immunization with sera from immunized 
mice was also successful (Neirynck et al. 1999). Since then, similar results have been obtained 
using different VLP carriers, such as Malva mosaic virus (MaMV) nanoparticles (Leclerc et al. 
2013), Tobacco mosaic virus coat protein (Petukhova et al. 2013), Potato virus X (Tyulkina et al. 
2011), Papaya mosaic virus (Denis et al. 2008), Human papillomavirus (Matić et al. 2011), 
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Woodchuck hepatitis virus-like particle (Ameiss et al. 2010), bacteriophages T7 and Qβ (Hashemi 
et al. 2012; Bessa et al. 2008) and even the transmembrane domain of haemagglutinin combined 
with the matrix protein M1 (Kim et al. 2013). Immunogenic VLPs can also be obtained by co-
expressing the matrix protein M1 with the native, full-length M2 protein (Song et al. 2011). 
Other carriers that do not form VLPs, but which enhance immunogenicity by acting as adjuvants, 
have also been exploited (Deng et al. 2015). Recently, Mardanova et al. (2015) successfully 
expressed M2e fused to bacterial flagellin in tobacco plants. These adjuvated molecules induced 
high, titres of anti-M2e antibodies by redirecting the response from the carrier flagellin towards 
the M2e epitopes; they also protected mice from lethal challenge with different strains of 
influenza A (Mardanova et al. 2015).  
There is, however, one important caveat to consider when designing universal vaccines based on 
M2e. In 2005, Liu et al. (2005), first reported after several M2e sequence analyzes across different 
species, that some regions on the M2e peptide can vary depending on the host species. They 
suggested that there is one specific M2e region that is consistent with host restriction specificities 
of human, avian and swine (underlined residues represent changes in amino acids): 
PIRNEWGCRCN (aa         10 - 20, human isolates), PTRNGWECKCS (aa 10 - 20, avian isolates), 
LTRNGWGCRCS (aa 10 - 20, avian origin/human isolates), and PIRNGWECRCN (aa 10 - 20, swine 
isolates) (Lee et al., 2014; Liu et al., 2005). These changes in sequences between different species 
could possibly reduce the spectrum and the efficacy of an M2e vaccine.  
To prevent this, some groups have been using tandem repeats of M2e epitope sequences of 
human, swine, and avian origin instead of just one single version. For example, Kim et al. (2013) 
successfully expressed a chimaeric protein composed of five different versions of M2e fused to 
the HA transmembrane domain in an insect cell-based system. This construct, when co-expressed 
with M1, successfully formed VLPs that incorporated heterologous M2e epitopes at significantly 
higher levels than on native influenza virions or in wild type M2 VLPs (M2WT). Intramuscular 
immunization with the chimaeric construct also induced higher levels of anti-M2e antibodies that 
conferred a wider range of cross reactivity to influenza virus than natural live virus infections or 
homologous M2e VLPs (Kim et al. 2013).  
24 
 
However, protection levels conferred by anti-M2 immunity have been the topic of a long and 
delicate debate amongst influenza researchers. While there are uncountable different proof of 
concept studies that show that anti-M2 immunity offers some correlate of protection in mice, 
extending these studies to other animals (ferrets or primates) has not always been satisfactory 
(Fan et al. 2004). On the other hand, some companies have proceeded to phase 1 clinical trials in 
humans and most of them resulted in positive safety profiles and good immunogenicity reports 
(Soema et al. 2015). One particular study on M2e-flagellin-conjugated vaccines has just recently 
completed a successful phase 2 trial (Turley et al. 2011). Phase 3 trials should be conducted in 
the coming years, and will provide much insight on the possibilities of these vaccines. 
Overall, it seems that the future is bright for universal influenza vaccines. Interestingly, the 
current opinion is that universal vaccines should be administered as a complement to seasonal 
vaccines, rather than as a replacement (Atsmon et al. 2014; Antrobus et al. 2014).                 
However, with many other universal influenza vaccine candidates under development, it is 
possible that future influenza vaccines will be composed of a cocktail of different conserved 
epitopes that together may offer strong, long lasting, and broad immune protection.  
1.4.2. Plant-made vaccines 
Besides conferring broader protection, future influenza vaccines should be produced at a much 
higher rate and in greater amounts than what is achievable today. With an estimated world 
population exceeding 9 billion by 2050, and with African countries probably seeing the highest 
increase (1.1 to 2.3 billion), it is simply unfeasible to continue producing expensive influenza 
vaccines from hens’ eggs. The recent H1N1 influenza outbreak in 2009 has showed us that an 
egg-based production system for influenza vaccines is not suitable for a quick large-scale 
response in face of a new highly pathogenic influenza strain and especially not for developing 
countries, who received vaccine stocks only in late 2010 (Mortimer et al. 2012).                                      
For these reasons, health authorities will have no choice but to completely reform the current 
influenza vaccine production system to a more modern one that can be easily and cheaply 
scalable to produce large amounts of influenza vaccines.  
25 
 
Over the past 20 - 30 years, plants have been extensively reviewed as production systems for 
various medically and industrially relevant proteins. The rationale for using plants relies on their 
safety, cost-effectiveness and scalability. Contrarily to egg,  microbial, insect and mammalian cell-
based systems, plants can be cheaply grown virtually anywhere without the requirement of 
dedicated facilities containing expensive equipment (Waheed et al. 2016; Pogue et al. 2010; 
Mortimer et al. 2012).  Moreover, this process can be rapidly and easily scaled up in response to 
sudden virus outbreaks or bioterrorism events (D’Aoust et al. 2010). Plants also do not harbor 
any known human pathogens such as prions or viruses, which makes them safe, and contributes 
significantly to the reduction of costs in both upstream and downstream processes (Horn et al. 
2004; Thuenemann et al. 2013).  Finally, as eukaryotic organisms, plants are able to produce 
complex eukaryotic proteins with correct folding, glycosylation, and activity (Horn et al. 2004).  
The first evidence that plants could produce pharmaceutically relevant proteins came from a 
study conducted by Barta et al. (1986), where transgenic tobacco plants where shown to be able 
to express human growth hormone (Barta et al. 1986). Shortly after this pioneering study, many 
therapeutics were produced for the first time in plants, including human monoclonal antibodies 
(During K. 1988), secretory antibodies (Hiatt et al. 1989), hepatitis B surface antigen (Mason et 
al. 1992) and various egg proteins (Zhong et al. 1999; Hood et al. 1997). These proteins were all 
produced by generating stable transgenic plant lines. It is important to note that transgenic plant 
technology is only suitable for the production of therapeutics once a seed bank has been 
established. Generating a de nova production of a seed bank is an exceptionally time-consuming 
and often costly process, not suitable for the discovery of new drugs. Nowadays, an alternative 
method using transient expression is favored for the rapid optimization of recombinant protein 
expression (Thuenemann et al. 2013; Sainsbury & Lomonossoff 2014).  
Transient expression can be generally performed in two ways: these are by directly using viral 
vectors such as those derived from Tobacco mosaic virus (TMV), or by agroinfiltration. The virus 
infection method is dependent on the ability of plant viruses to deliver foreign genes into plants 
in a rapid and systemic way (Schillberg et al. 2005). However, these are limited to a narrow range 
of hosts and gene size, and administration can sometimes be difficult, especially for RNA viral 
vectors (Rybicki 2010). Agroinfiltration on the other hand, relies on whole-plant infiltration with 
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a suspension of recombinant Agrobacterium tumefaciens containing the desired plant expression 
construct. When injected into the plant leaves, A. tumefaciens mediates the transfer of its T-DNA 
to the nucleus of plant cells in a highly efficient manner, where it can express the transgene at 
very high levels without stable transformation. This process only takes a few days to complete, 
versus several months when using transgenic plants. Although agroinfiltration was initially 
developed to quickly test different gene constructs before more traditional approaches could be 
used, the recent development of silencing suppressors and industrial-scale vacuum equipment 
has made it possible to use agroinfiltration for large-scale production of recombinant proteins 
(D’Aoust et al. 2008). Moreover, agroinfiltration can also be used to deliver virus-based vectors, 
thus combining the advantages of both these methods of transient expression (Rybicki 2010). 
A wide variety of recombinant proteins have been successfully expressed in plants via 
agroinfiltration, from which a significant proportion are currently at various stages of clinical trials 
or at the verge of being commercialized (Huafang Lai & Jake Stahnke 2013; Bhaskar et al. 2009; 
Obembe et al. 2011). Probably the most relevant example to this study comes from Medicago® 
Inc. and their plant-produced avian flu H5 pandemic vaccine candidate which is currently in phase 
2 clinical trials. They showed that by adopting a large-scale agroinfiltration system, they could 
express recombinant HA with yields up to 50 mg⁄ kg of leaves. These recombinant HA molecules 
assembled correctly into highly immunogenic VLPs that budded at the plasma membrane and 
conferred complete protection against a lethal challenge with a heterologous 
(A⁄Vietnam⁄1194⁄04 (H5N1)) virus (D’Aoust et al. 2008). Moreover, they reported being able to 
obtain a purified product only 3 weeks after receiving the HA sequence, which is approximately 
8 times faster than the response given by governments to the 2009 H1N1 pandemic (D’Aoust et 
al. 2010).  
1.5. Aims of the study 
The overall aim of this project, was to design a universal candidate vaccine for influenza that can 
be rapidly and cheaply produced. To achieve this, I compared several studies on universal 
influenza vaccines and vaccine production systems. Based on my research, I first hypothesized 
that, N. benthamiana plants could be used to rapidly express M2e-HA chimaeric proteins.             
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And secondly, that these chimaeric proteins would self-assemble into VLPs with potential to elicit 
broad immune responses. 
The aim of the first part of this study was to produce antibodies against the influenza M1 and M2 
proteins. These antibodies would be used for the remainder of the project as reagents, thus 
removing the necessity to buy expensive commercial antibodies. For this, both M1 and M2 were 
produced in E. coli and subsequently used to raise antibodies in rabbits. Moreover, the proteins 
expressed in E. coli were also used as positive controls on acrylamide gel and western blots. 
The second part of the project involved designing chimaeric proteins using the M2e peptide and 
HA protein. This was based on previous work performed by Kim, Lee, et al. (2013), where tandem 
copies of the M2e peptide were genetically fused to the HA transmembrane domain and 
expressed in insect cells (Kim, Lee, et al. 2013). When supplemented with the core protein M1, 
these fusion proteins successfully assembled into immunogenic VLPs capable of conferring cross-
protection in mice. After such promising results, I decided to test whether similar VLPs could be 
obtained for the first time using a plant expression system, which would be more adaptable to 
the current demand for influenza vaccines. To increase the chances of VLP formation in plants, I 
designed six variations of the M2e-HA chimaera. The expression of these fusion proteins was 
optimized in plants using different conditions and expression vectors. 
Finally, after selecting the most promising constructs, I proceeded with density gradient 
purification of the fusion proteins and analyzing if they formed VLPs using transmission electron 
microscopy (TEM). Furthermore, the effect of M1 co-expression on VLP formation was also 
investigated. 
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Chapter 2: Expression of influenza A M1 and M2 proteins in E. coli 
2.1. Introduction  
For the last few decades, the gram-negative bacterium Escherichia coli has dominated bacterial 
expression systems and remained the preferred organism for early laboratory investigations 
(Chen 2012). One of the reasons for this is that E. coli has been extensively genetically 
characterized and manipulated. Many techniques to increase recombinant protein production in 
E. coli have been explored, and there are an increasingly large number of different cloning vectors 
and mutant host strains widely available from commercial sources and public repositories, 
allowing for the expression of a vast number of different proteins (Sivashanmugam et al. 2009). 
E. coli can also be easily transformed with minimal amounts of foreign DNA and has unparalleled 
growth kinetics, which permits easily reaching high recombinant cell density cultures in short 
periods of time (Pope & Kent 1996; Rosano & Ceccarelli 2014).  
However, since it is a prokaryotic based system, heterologous eukaryotic proteins expressed in 
E. coli may not be correctly folded or have the correct post-translational modifications such as 
glycosylation and disulfide bridge formations, thus they may lack or have decreased biological 
activity (Kamionka 2011). Moreover, when expressed in large amounts, recombinant proteins in 
E. coli often precipitate and aggregate, forming inclusion bodies that are difficult to purify (Khow 
& Suntrarachun 2012). Finally, E. coli produces high amounts of lipopolysaccharide (LPS) 
endotoxins, which are pyrogenic in humans and other mammals. Hence if they are intended for 
animal testing, proteins must first be purified to become endotoxin-free (Terpe 2006).  
Nevertheless, there are ways to combat the disadvantages mentioned above. Apart from correct 
protein folding, which can be lengthy and fastidious to solve, inclusion bodies and endotoxins can 
be easily circumvented in relatively small-scale expressions. Hence, when compared to the high 
costs and lengthy optimization processes involved in most eukaryotic expression systems, E. coli-
based expression becomes a more attractive offer for small scale, laboratory-sized experiments. 
In this section of the study, I set out to produce antibodies in rabbits against the two influenza 
matrix proteins M1 and M2. Since these antibodies would be used to detect recombinant protein 
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expression in plants only, I had to use antigens that were produced in a different organism (i.e. 
E. coli) to reduce cross-reactivity. To produce these antibodies, I had to express and purify M1 
and M2 in sufficient amounts that would induce a significant immune response in rabbits.  For 
this, I used the pPROEX-HT (Life Technologies, USA) prokaryotic expression vector which contains 
an isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible trc promoter and lacIq repressor gene. 
The synthetic trc promoter is commonly used for its ability to drive high-level transcription of 
genes (Tegel et al. 2011). 
The serum from immunized rabbits would facilitate the detection of both influenza matrix 
proteins produced by different expression systems, including in plants. The sera derived from M2 
immunization should also allow for detection of M2e-fused proteins, since the M2e region 
contains most immunogenic epitopes (Frace et al. 1999; Zou et al. 2005; Fu et al. 2009). At the 
same time the E. coli produced M1 and M2 proteins were also used as positive controls in western 
blots, as discussed in Chapter 3. 
2.2. Methods 
2.2.1. Construction of pPROEx-M1 and pPROEx-M2 
Human codon optimized cDNAs coding for influenza matrix proteins M1 and M2 (Genbank 
accession number: AY651387.1; only one accession number because the M1 protein is encoded 
on the seventh RNA segment together with the M2 protein) were supplied by Genscript in the 
pUC57 vector. The bacterial expression vector pPROEx-HTb (Thermo Fisher Scientific, MA, USA) 
was chosen to express both proteins in E. coli. pPROEx-HTb is a T7 promoter-based expression 
vector that is frequently used to obtain high levels of recombinant proteins in E. coli (Ochocka et 
al. 2003). It contains the lacIq repressor gene, which enables IPTG-induced expression of the 
inserted gene from the promoter and a 6-histidine tag that allows for easy protein detection via 
western blots. 
To facilitate cloning into pPROEx-HTb, the M1 gene was designed with a 5’ AflIII and a 3’ XhoI 
restriction site. The M2 gene did not contain any 5’ restriction sites that allowed cloning into 
pPROEx-HTb. Therefore, the pUC57-M2 plasmid was used as template DNA in a subsequent PCR 
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DNA amplification to add an AlfIII restriction site at the 5’ terminus to allow cloning into the 
pPROEx-HTb vector. The primers used for the PCR reaction are listed in Table 1.  
Table 1| Primers for E. coli expression 
Primer Sequence RE added Orientation 
M2F 5’-TTT ACA TGT CTC TGC TGA C-3’ AflIII Forward 
M2R 5’-TCT CGA GCT TAT TCC AGT TCA ATG T-3’ - Reverse 
M1F 5’-TGT CCT GAG TAT TAT CCC-3’ - Forward 
M1R 5’-GAC CCC CAT CCT TTT CTG-3’ - Reverse 
 
The PCR reaction mixes consisted of 50 ng of the appropriate template DNA, 200 μM dNTPs,        
0.5 μM of each primer, 2 mM Mg2+, 1 x Accuzyme buffer and 1.25 units (U) AccuzymeTM DNA 
Polymerase (Bioline, Meridian Bioscience Inc., USA). The reactions were amplified with an initial 
denaturation step at 95 °C for 2.5 min. Followed by twenty-five cycles of denaturation at 95 °C 
for 30 s, annealing at 49 °C for 30 s and elongation at 72 °C for 1 min. A final elongation step at 
72 °C for 2 min was carried out at the end of the PCR run. The amplified product was separated 
on 0.8% w/v TBE (89 mM Tris base, 89 mM boric acid and 2 mM EDTA [pH 8]) agarose gels 
containing 00.5 mg/mL ethidium bromide and visualized under short wavelength ultraviolet (UV) 
illumination. O’GeneRuler™1kb DNA ladder #SM1163 (Thermo Fisher Scientific, MA, USA) was 
used as molecular weight marker on all the agarose gels.   
DNA was purified from the agarose gels using the QIAquick® Gel Extraction kit (Qiagen, USA) 
following the manufacturer’s instructions. The purified DNA was ligated into the pJET®-TEasy 
Vector system (Thermo Fisher Scientific ©, USA) according to the manufacturer’s instructions and 
incubated overnight (O/N) at 4 °C. 
The ligated pJET-M2 and the original pUC57-M1 plasmids were used to transform DH5-α 
chemically competent E. coli cells (E. cloni™, Lucigen) according to the method described by 
Sambrook et al. (1989). The transformed cells were plated on Luria Bertani (LB) media agar plates 
(Luria-Bertani media (LB): 10 g Tryptone, 5 g Yeast Extract, 5 g NaCl in 1 litre water; 15 g of 
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Bacterial Agar was added for agar plates) supplemented with ampicillin (amp) (100 μg/mL). Plates 
were incubated at 37 °C, overnight. 
Positive colonies were selected by colony PCR using gene-specific primers for pUC57-M1 and pJET 
specific primers for pJET-M2 as showed in Table 1. The pUC57-M1 PCR reactions of the 
appropriate template DNA consisted of 250 μM dNTPs, 0.2 μM of each primer, 1 x Kapa taq Buffer 
A and 0.5 U KAPA Taq DNA Polymerase (KAPA Biosystems). The reactions were amplified with an 
initial denaturation step at 95 °C for 4 min; followed by twenty-five cycles of denaturation at 95 
°C for 30 s, annealing at 47 °C for 30 s and elongation at 72 °C for 30 s. Reactions finished with a 
final elongation step at 72 °C for 4 min. The pJET-M2 PCR reaction was done according to 
manufacturer’s instructions using pJET specific primers.  
Positive colonies containing either pUC57-M1 or pJET-M2 were inoculated into 10 mL LB broth 
supplemented with 50 μg/mL ampicillin and incubated with agitation for 16 hrs at 37 °C. Plasmid 
isolations were performed using the QIAprep® Spin Miniprep kit (Qiagen, USA) according to 
instructions provided by the manufacturer.  
The plasmid DNA was sequenced (Macrogen Inc., Netherlands) using the gene-specific primers 
(Table 1). Sequencing data were analyzed using CLC MAIN WORKBENCH software (Qiagen, USA). 
Subcloning into pPROEx-HTb 
The M1 and M2 encoding sequences were first excised from the pUC57 and pJET backbone 
respectively, by digesting the plasmid DNA (~2000 ng) with 1U of AflIII and XhoI (Thermo Fisher 
Scientific, MA, USA) for 1 hr at 37 °C. Digested DNA was separated on a 0.8 % w/v TBE agarose 
gel and the corresponding band was gel-purified with the QIAquick® Gel Extraction kit (Qiagen). 
This digestion yielded recombinant DNA with 5’ AflIII and 3’ XhoI restriction sites. 
The pPROEx-HTb expression vector was supplied by Thermo Fisher Scientific © and linearized by 
restriction digestion with 1 U of NcoI and XhoI (Thermo Fisher Scientific, MA, USA) for 1 hr at 37 
°C. After digestion, the vector DNA was dephosphorylated using 1 U rapid alkaline phosphatase 
(Roche) according to the manufacturer’s instructions. 
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Recombinant DNA sequences were then directionally sub-cloned into pPROEx-HTb according to 
their respective restriction sites using T4 DNA Ligase (Thermo Fisher Scientific, MA, USA). 
Recombinant clones were transformed into DH5-α chemically competent E. coli cells (E. cloni™, 
Lucigen) (Sambrook et al. 1989). Transformed cells were plated on LB media plates supplemented 
with ampicillin (100 μg/mL) O/N at 37 °C. Positive clones were selected by colony PCR using the 
same settings and gene-specific primers (Table 1) as previously. Successful recombinants were 
grown overnight and stored at -80 oC in 50 % glycerol. 
2.2.2. Protein expression 
Small-scale induction 
Single colonies of recombinant pProEX-HTb clones were placed in 10 ml LB media with 100 µg/ml 
ampicillin and incubated O/N at 37 oC. Overnight cultures were sub-cultured into 10 ml of either 
LB media or Terrific broth (Terrific broth (TB): 12 g tryptone, 24 g yeast extract, 9.4 g K2HPO4, 2.2 
g KH2PO4, 4 mL of glycerol in 1 litre water, pH 7.2) media supplemented with 100 µg/ml ampicillin. 
The cultures were allowed to grow at either 28 oC or 37 oC until they reached an OD590 between 
0.5 and 1. After removing a 1 ml uninduced aliquot from each culture, IPTG was added at various 
final concentrations (0.4 mM, 0.6 mM and 0.8 mM). After induction, aliquots (1 ml) of bacteria 
were removed every hour for 3 hours for each construct. An aliquot after 16 hrs induction 
(overnight) was also removed. The samples were centrifuged at 10,000 rpm for 10 min and each 
pellet harvested, pooled and weighed. Pellets were re-suspended in 4X BugBuster™ Protein 
Extraction Reagent and extraction protocol followed as per the manufacturer’s instructions 
(BugBuster™, Novagen) to separate soluble/insoluble fractions. 
Large scale induction 
One liter of Terrific broth media (0.6 mM IPTG) or 1 L LB media (0.6 mM IPTG) was used to grow 
recombinant bacteria containing pPROEx-M2 or pPROEx-M1 respectively. These were allowed to 
grow for 16 hrs at 28 oC for M2 or at 37  oC for M1. After induction, cell pellets were harvested by 
centrifugation at 10,000 rpm for 10 min and insoluble fractions were collected using                               
4 X BugBuster™ Protein Extraction Reagent as previously. Endotoxin-free Dulbecco’s Phosphate 
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Buffered Saline (PBS) D8662 (Sigma-Aldrich, Merck, Germany) was used in the final wash steps 
instead of the BugBuster™ reagent before protein sample analysis. 
2.2.3. Coomassie stained SDS-PAGE gels and western blots 
For SDS-PAGE analysis, 5 X loading dye containing β-mercaptoethanol was added to protein 
extracts, and samples were incubated at 95 °C for 10 min. These were then loaded at equal 
volumes (30 uL) on 10% SDS-polyacrylamide gels using the Mini-PROTEAN® Tetra SDS-PAGE 
system (Bio-Rad, CA, United States of America), and electrophoresed at 120V for approximately 
120 minutes. To determine the sizes of the resolved proteins in Coomassie stained gels and on 
nitrocellulose membranes, a Color Protein Standard Broad Range Ladder #P7712S (New England 
Biolabs, USA) was used as a molecular weight marker.  
For Coomassie, gels were stained with Coomassie Brilliant Blue R250 (Merck, Darmstadt, 
Germany) stain for 2 hrs at 37 °C and destained overnight with destain solution (45 % methanol, 
45 % water, 10 % glacial acetic acid).  
For western blots, gels and nitrocellulose membranes were pre-equilibrated for 10 minutes in 
transfer buffer (5.82 g Tris base, 2.93 g glycine, 200 mL methanol in 1 L water, pH 9.2) before 
being transferred to a nitrocellulose membrane at 15V for 90 minutes using a Trans-blot®SD 
semi-dry transfer cell (Bio-Rad, CA, USA). After electrophoretic transfer, the membranes were 
blocked in blocking buffer (5 % non-fat dairy milk and 1 x PBST (137 mM NaCl, 1.8 mM KH2PO4, 
10 mM Na2HPO4, 2.7 mM KCl, pH 7.4and 0.1% Tween-20) for 30 min. The membranes were 
probed overnight at 4 °C with either 1:2000 anti-histidine MCA 1396 mouse monoclonal IgG 
antibody (ABD Serotec, Bio-Rad, CA, United States of America), 1:5000 anti-M2 14C2 mouse 
monoclonal IgG antibody (Abcam, UK), or rabbit serum (at the specified dilution) diluted in 
blocking buffer. The membranes were then washed four times with blocking buffer for 15 
minutes each and afterward incubated in a 1:10,000 dilution of anti-mouse IgG (whole molecule) 
alkaline phosphatase conjugated antibody A3562 produced in goat (Sigma-Aldrich, Merck, 
Germany) or goat anti-rabbit IgG alkaline phosphatase conjugate (1:5000, Sigma) in blocking 
buffer for 1 hour at 37 °C. Membranes incubated in secondary antibody were washed four times 
with 1x PBST (without milk), with 15 minutes for each wash. Detection was performed with 5-
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bromo, 4-chloro, and 3-indolylphosphate (BCIP) (KPL, MD, United States of America). The 
membranes were washed with distilled water once bands were visible after 1 hr to stop the 
developing reaction. Protein expression, extraction and western blot analysis was repeated at 
least three times to confirm the expression of the recombinant influenza proteins. 
2.2.4. Protein quantification 
Standard BSA curves were constructed by loading varying amounts of bovine serum albumin 
(BSA) (#23210, Thermo Fisher Scientific, MA, USA) ranging from 0.3 µg/uL to 1.0 µg/uL onto SDS-
PAGE gels. Concurrently, the insoluble fractions containing M1 or M2 influenza proteins were 
loaded on the same gel with varying dilutions ranging from 1 to 1:10. The proteins were diluted 
with sterile PBS and protein loading dye for SDS-PAGE gels. The quantitation of bands was 
performed using GeneTools software (Synoptics Inc., UK). 
2.2.5. Endotoxin assay 
Levels of endotoxin were measured using a ToxiSensorTM chromogenic LAL Endotoxin Assay Kit 
L00350 (Genscript, China) as per the manufacturer’s instructions. The absorbance readings were 
performed using Immuno 96-microwell clear solid plates (Thermo Fisher Scientific, MA, USA) and 
a BioTek Powerwave XS plate reader (BioTek, USA). 
2.2.6. Polyclonal antibody production in rabbits: inoculation schedule 
Four female New Zealand White rabbits of approximately 3 months old were used (2 per antigen). 
The amount of protein was divided equally into 4 tubes for each antigen (for the initial and three 
booster injections; see below). Each tube contained 0.5 mL of a suspension of the inclusion 
bodies in PBS and 0.5 mL of Freund’s incomplete adjuvant (IFA). The total amount of antigen 
injected in each dose was approximately 75 µg for M1 and 56 µg for M2. Each inoculation 
consisted of two injections of 0.5 mL in two different sites (making the total amount of protein 
injected per inoculation: 150 ug for M1 and 112 ug for M2).  
Inoculations and handling of animals were performed by Rodney Lucas at the Research Animal 
Facility, UCT Health Sciences Faculty, as follows: 
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Pre-bleed: Ten milliliters pre-immune blood was collected from the central ear vein of each 
rabbit, 3 days prior to administration of the antigen.  
Initial inoculation: Animals were injected subcutaneously on the back at two sites with 0.5 mL 
(per site) of the antigen in the presence of Freund’s incomplete adjuvant (IFA). 
1st Boost: The first boost was performed 14 days after the initial inoculation (as above) with IFA. 
Ten milliliters blood was collected before boost, from the central ear vein of each rabbit. 
2nd Boost: The second boost was performed 7 days after the first boost (as above) with IFA.         
Ten milliliters blood was collected before boost, from the central ear vein of each rabbit. 
3rd Boost: The third and last boost was performed 7 days after the second boost (as above) with 
IFA. Ten milliliters blood was collected before boost, from the central ear vein of each 
rabbit. 
Collection of serum: Fourteen days after the last boost, rabbits where exsanguinated and blood 
was collected in coagulant tubes to harvest serum. 
Animal ethics approval for this research was granted by the Health Sciences Faculty Research 
Ethics Committee at the University of Cape Town - AEC Reference number 013/008. 
2.2.7. Pre-absorption of rabbit sera  
Where specified, rabbit sera were pre-absorbed against cell lysate from uninduced E. coli to 
reduce background. Nitrocellulose membrane was covered with E. coli cell lysate and incubated 
at room temperature on an orbital shaker for 2 hours. The cell lysate was discarded and the 
membrane was washed 4 x 15 mins with blocking buffer. The membrane was then incubated 
with rabbit serum, diluted in blocking buffer, for 2 hours. The membrane was discarded and the 
pre-absorbed rabbit serum was then used for immunoblotting or stored at           -20 °C 
2.2.8. Indirect ELISA 
The anti-M1 and anti-M2 response in rabbit sera was determined by indirect ELISA. 96-well 
Maxisorp® microtitre plates (Nunc) were coated with 100 μL/well of antigen diluted in coating 
buffer (10 mM Tris, pH 8.5). For anti-M1 tests, plates were coated with the following diluted 
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plant-produced proteins: M1 as experimental sample and 5xM2e-HAtrans as negative control 
(Chapter 3). For anti-M2 tests, plates were coated with the following plant produced proteins: 
5xM2e-HAtrans as experimental samples and M1 as negative control. The anti-M2 serum was 
further tried against a synthetic M2e peptide – SLLTEVETPIRNEWGCRCNDSSD – (Genscript, 
China). After incubating the plates O/N at 4 °C, plates were blocked with TBS blocking buffer           
(5 % non-fat dry milk in 1 x TBS [50 mM Tris, 150 mM NaCl, pH 7.5]) for 2 hrs at RT after which 
they were washed four times with 1 x TST buffer (1 x TBS [pH 7.5], 0.05 % Tween®20). One 
hundred microliters of corresponding final bleed sera were then added at several dilutions in TBS, 
after which plates were left for 1 hr at 37 °C for incubation. For M2 plates, the anti-M2 14C2 
monoclonal IgG antibody produced in mouse (Abcam, UK) was used as positive control. Blank 
wells containing no antibody were included as background control. After incubation, plates were 
washed four times with 1 x TST buffer and 100 μL of goat anti-rabbit IgG alkaline phosphatase 
conjugate (1:5000, Sigma) diluted in blocking buffer was added per well and incubated for 1 hr 
at 37 °C. After incubation, the plates were washed four times with 1 x TBS (pH 9) buffer and 200 
μL SIGMAFAST™ p-Nitrophenyl phosphate (pNPP, Sigma) was added per well. The plates were 
developed in the dark for 30 min after which the absorbance was detected at 405 nm on a           
BIO-TEK® Powerwave XS microtitre plate reader. 
To determine the anti-M1 binding titers, rabbit serum from pre-bleed, 1st boost, 2nd boost, and 
final bleed was diluted in TBS blocking buffer in a 5-fold series in triplicate ranging from a             
1:50 dilution to 1: 12,150 and used in an indirect ELISA as described above. 
2.2.9. Statistical analysis 
A two-tailed, non-paired t-test using the Holm-Sidak method was employed to calculate 
statistical significance of the final bleed anti-M2 or M1 response, as compared to the negative 
control antigen (p = 0.001). Statistical analysis was carried out using GraphPad Prism v 7.01 
(GraphPad Software, Inc.). 
37 
 
2.3. Results 
2.3.1. Cloning into pPROEx-HTb 
Both M1 and M2 genes were supplied from Genscript, China. Before subcloning into the bacterial 
expression vector pPROEx-HTb, M2 had to be modified by PCR using the M2 primers from table 
1, to include a 5’ AflIII restriction site (data not shown). After adding the necessary restriction 
sites, M1 and M2 were excised from the pUC57 backbone by digesting with AflIII and XhoI 
restriction enzymes. The bands corresponding to the genes of interest were gel-purified; yielding 
genes flanked with 5’ AflIII and 3’ XhoI restriction sites (data not shown). These were then 
subcloned into pPROEx-HTb, which had been previously linearized using NcoI and XhoI. After 
digestion and ligation, all recombinant clones were transformed into E. coli. Colony PCR allowed 
to detect positive clones as bands of ~0.3 kb and ~0.7 kb (corresponding to M2 and M1 
respectively) were observed (figure 1A and B). The identity of recombinant DNA was further 
confirmed by sequencing (data not shown).  
 
Figure 1| Colony PCR of pPROEX recombinant clones confirms the presence of inserts. A) PCR of 
recombinant pPROEx-HTb-M2 clones using M2 primers detailed in Table 1. The M2 gene is 
approximately 270 Bp. B) PCR of recombinant pPROEx-HTb-M1 clones using M1 primers detailed in 
Table 1. The M1 gene is approximately 670 Bp. M – Marker. Arrows indicate desired DNA band. 
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2.3.2. Optimizing M2 expression 
Small-scale protein expression trials of recombinant bacteria containing pPROEx-M2 were 
conducted with harvesting of cell samples at 1, 2 and 3 hrs post-induction with 0.6 mM IPTG. The 
cells were sampled at different time points to determine the effect of incubation time on protein 
yield. Separation of soluble and insoluble fractions was also performed to analyze the solubility 
of the recombinant protein. This was performed using BugbusterTM, which is a mixture of 
detergents that achieves efficient lysis of bacterial cells. Immunoblotting of induced whole cells 
showed that M2 was only expressed after 2 hrs post induction and at low levels. Only the 
insoluble fraction showed bands corresponding to the M2 size (Figure 2). Moreover, the OD600 of 
recombinant E. coli rapidly decreased after induction; going from 0.65 (pre-induction) to              
0.49 (3 hrs post-induction). Hence, expression was later optimized by using different IPTG 
concentrations (0.4 mM, 0.6 mM and 0.8 mM), longer periods (i.e. 16 hrs) and different 
temperatures (37 oC vs 28 oC) to try increase recombinant protein levels without killing the 
recombinant bacteria (data not shown). From these experiments, I observed an increase in 
protein levels as well as a decrease in bacterial lysis when the recombinant bacteria were induced 
at lower temperatures (i.e. 28 oC) and for longer periods (i.e. 16 hrs) (data not shown). The 
Figure 2| M2 expression in E. coli. Western blot of the soluble and insoluble fractions of recombinant E. 
coli expressing the M2 protein after IPTG induction. Anti-histidine tag antibody (1:2000) was used to 
detect the influenza protein. M – molecular marker; t0 - uninduced cells; t1 – 1 hour post-induction; t2 
– 2 hours post-induction; t3 – 3 hours post-induction. Arrow indicates the position of the respective 
protein (± 17 kDa). 
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combination of these two parameters yielded the best results. Lowering IPTG concentrations did 
decrease bacterial lysis but at the expense of lower protein levels. Hence it was determined that 
best expression could be obtained by inducing with 0.6 mM IPTG for 16 hrs at 28 oC; although 
protein levels remained relatively low as they could not be detected on a Coomassie stained SDS-
PAGE gel. It is important to note that M2 was never observed in the soluble fraction.  
To try and further increase protein levels, an enriched media (Terrific broth) was used during 
induction instead of LB. Immunoblot of induced cells in either LB or Terrific broth media, showed 
significantly increased levels of M2 in TB compared to LB (Figure 3) using the optimal conditions 
mentioned previously (i.e. 0.6 mM IPTG for 16 hrs at 28 oC). I also observed that the OD600 of 
recombinant bacteria increased when TB was used (0.81 to 0.92 in TB vs 0.8 to 0.69 in LB). 
Moreover, soluble protein was observed for the first time using TB (Figure 3). Finally, it appears 
that M2 formed multimeric structures as observed from the increased molecular weight bands 
(Figure 3, red arrows). From these results, it was determined that the best conditions to express 
M2 in E. coli was by inducing in TB media supplemented with 0.6 mM IPTG for 16 hrs at 28 oC.  
Figure 3| The effects of different induction media on M2 expression in E. coli. Western blot of 
recombinant E. coli grown in either LB or TB induction media. Soluble and insoluble fractions were 
extracted after induction with IPTG (0.6 mM) for 16 hrs at 28 oC. Anti-histidine tag antibody (1:2000) was 
used to detect the influenza protein. M – molecular marker; LB – Luria Broth; TB – Terrific Broth.  Black 
arrow indicates the position of the respective protein (± 17 kDa), red arrows indicate the position of 
putative M2 multimers. 
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2.3.3. Optimizing M1 expression 
As for M2 expression, small-scale protein expression trials of recombinant bacteria containing 
pPROEx-M1 were conducted to determine best expression conditions. Cell samples were 
harvested at 1, 3 and 16 hrs post-induction with 0.6 mM IPTG, and soluble/insoluble fractions 
were collected to analyze the solubility of M1 in E. coli.  Unlike M2, M1 was present in both 
soluble and insoluble fractions; the most protein was found in the insoluble fractions after 16 hrs 
of induction (Figure 4). Only the insoluble fractions showed a band on Coomassie stained SDS-
PAGE gels (data not shown). Also, from Figure 4, higher bands (kDa) can be observed in the 
insoluble fractions, which could correspond to M1 dimers. 
To try increase the solubility of M1, expression was tried under different conditions (as for M2 
expression). However, no significant change could be observed when using TB media, lower IPTG 
concentrations or lower incubation temperatures, with most of the protein still being in the 
insoluble fraction (data not shown). Hence, given the high levels of expression obtained using 0.6 
mM IPTG, it was decided to continue using the insoluble fraction after induction with 0.6 mM 
IPTG for 16 hrs at 37 oC. 
Figure 4| Small-scale expression of M1 in E. coli. Western blot of the soluble and insoluble fractions of 
recombinant E. coli expressing the M1 protein after IPTG induction. Anti-histidine tag antibody (1:2000) 
was used to detect the influenza proteins. +ve – M2 expressed in E. coli; M – molecular marker; t0 - 
uninduced cells; t1 – 1 hour post-induction; t3 – 3 hours post-induction; t16 – 16 hours post-induction. 
Arrow indicates the position of the respective protein (± 27 kDa). 
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2.3.4. Large-scale expression of proteins for rabbit inoculation 
To produce sufficient amounts of protein for rabbit inoculation, recombinant bacteria containing 
pPROEx-M2 and pPROEx-M1 were grown in 1 L media using the respective conditions mentioned 
in the sections above.  
Before quantifying the proteins, an enrichment using nickel affinity purification was attempted 
by first denaturing inclusion bodies using 8M UREA (data not shown). However, this was not 
successful as the yields recovered were insufficient for rabbit inoculation. Since in both cases, 
most protein was found in inclusion bodies (insoluble fractions), I proceeded with using these for 
the remaining of the experiments. Inclusion bodies were washed with Endotoxin-free Dulbecco’s 
Phosphate Buffered Saline (PBS) to reduce bacterial endotoxins in the protein samples. After the 
washing steps, recombinant protein amounts were estimated using serial dilutions of bovine 
serum albumin (BSA) loaded for SDS-PAGE and stained with Coomassie Blue. 
After quantification, the protein samples had to be tested for their levels of bacterial endotoxin 
using the ToxiSensorTM chromogenic LAL Endotoxin Assay Kit L00350 (Genscript, China).          
From this test, it was estimated that the inclusion bodies containing M2 had an average of 122 
EU/mL whereas the M1 inclusion bodies had significantly higher levels at 613 EU/mL. Since 
  0.5   0.25 0.13 0.63  0.3    M  1/10  1/4   1/2  Und 
BSA (ug/uL) M2 
 1.0    0.5  0.25 0.13 0.63    M   1/10  1/4  1/2   Und 
BSA (ug/uL) M1 
Figure 5| Quantification of proteins using BSA as a standard. Coomassie-stained SDS-PAGE gel of M2 
(A) and M1 (B) serial dilutions after large-scale expression. M – molecular marker. Arrows indicate the 
position of the respective proteins. 
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rabbits cannot take more than 100 EU/mL per inoculation (Malyala & Singh 2008), both samples 
had to be diluted in endotoxin-free Dulbecco’s PBS to reduce the amount of endotoxins. The final 
antigen doses that were injected into rabbits were 112 ug per 0.5 mL injection for M2 and 150 
ug per 0.5 mL injection for M1. The inoculation of rabbits was done by Rodney Lucas at the UCT’s 
Research Animal Facility per the protocol detailed in the Methods section. 
2.3.5. Testing of animal sera 
After inoculation trials, I proceeded with extraction and testing of animal sera to check for the 
presence of specific antibodies against M2 and M1. For this, I firstly used the final serum (day 42) 
produced by the rabbits in immunoblots to probe against M2 and M1 produced in bacteria 
(Figure 6A and B). The specificity of the final serum was compared to serum obtained before 
antigen injection (pre-bleed) and to commercial monoclonal antibodies. 
Western blot analysis of E. coli produced M2 with serum produced from rabbits 
As can be observed in Figure 6A, probing with the anti-his monoclonal antibody resulted in 
detection of a band of approximately 15 kDa corresponding to M2 monomers, together with a 
higher band at round 30 kDa possibly corresponding to dimers. On the other hand, probing the 
membranes with rabbit final or pre-bleed serum resulted in a non-distinguishable band pattern 
(similar for both final and pre-bleed serum) that should correspond to E. coli host proteins (this 
was expected since the antigens used to inoculate rabbits were made in E. coli).          
Unfortunately, these non-specific bands made it very difficult to see if the M2 protein was being 
detected. To try and remove some of the non-specific bands I tried diluting the serum up to 
1/20000, as well as pre-absorbing the serum against proteins from un-induced E. coli; however, 
none of these trials resulted in clearer band patterns (data not shown).  
Western blot analysis of E. coli produced M1 with serum produced from rabbits 
As previously demonstrated, detection of E. coli-produced M1 with an anti-his antibody resulted 
in a relatively clean band of approximately 27 kDa. However, as figure 6B shows, detection using 
serum from rabbits injected with M1 resulted in a complex band pattern.                           
Nevertheless, it is possible to distinguish within the background signal, one band of 
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approximately the same size as M1 on the lane probed with the final serum. This band of 
approximately 27 kDa is not visible on the lane probed with pre-bleed serum indicating that there 
are probably M1-specific antibodies in the final serum. Serum pre-absorbing was also done to try 
to remove non-specific antibodies, however, this resulted in a loss of both background and M1 
signal (data not shown).  
Western blot analysis of M2 and M1 produced in different expression systems 
An additional immunoblot test of the rabbit sera was carried out to determine if it could detect 
proteins expressed in tobacco plants. For this, the plant-produced cytoplasm targeted           
5xM2e-HAtrans and the M1 protein (both expressed using the pRIC vector, see Chapter 3) were 
used to test the anti-M2 and anti-M1 serum respectively.  
As previously shown with E. coli-produced proteins, it was not possible to distinguish specific 
bands when using the anti-M2 sera (Figure 7A). The plant-produced 5xM2e-Hatrans runs at 
approximately 30 kDa (with higher molecular weight multimers of ± 60 and 120 kDa) as shown 
using the monoclonal 14C2 anti-M2 antibody; although the final M2 sera does pick up a band of 
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Figure 6| Detection of M2 and M1 proteins produced in E. coli with rabbit sera. Immunoblots of                 
E. coli-produced M2 (A) detected with anti-M2 rabbit sera and E. coli-produced M1 (B) detected with 
anti-M1 rabbit sera. Both sera were at 1/2000 dilution.   M – Molecular marker; Final – Final bleed serum; 
Pre – Pre-bleed serum; +ve – Proteins detected with commercial anti-histidine antibody. Arrows indicate 
the position of the respective proteins (± 17 kDa M2 and ± 27 kDa M1). 
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approximately 60 kDa on the lane loaded with plant produced 5xM2e-HAtrans, a band of this size 
is also visible in the pre-bleed lane (Figure 7A). Overall, it was not possible to confirm the 
presence of M2 specific antibodies using immunoblots. 
On the other hand, it appears that the anti-M1 serum is able to pick up both bacterial and plant 
expressed proteins as shown by the 25 kDa and 27 kDa bands on Figure 7B corresponding to the 
plant-produced and bacterial-produced M1 protein respectively. It is worth noting that the plant-
based M1 does not contain a Histidine tag which explains the lower molecular weight. Also, 
diluting the M1 serum resulted in fewer non-specific bands, especially for the plant produced 
protein. 
Indirect ELISA for detection of anti-M2 and anti-M1 antibodies in rabbit sera 
To more accurately confirm the presence (or absence) of specific antibodies in the rabbit sera, a 
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Figure 7| Reactivity of rabbit sera with proteins produced in different expression systems. 
Immunoblots with M2 (A) and M1 (B) rabbit sera. Lanes labelled E contain E. coli-produced M2 or M1 
and lanes labeled P contain plant produced 5xM2e-HAtrans or M1. A) Proteins were detected with either 
commercial anti-M2 antibody (commercial; 1/5000); Final bleed anti-M2 rabbit serum (Final; 1/1000); 
or Pre-bleed anti-M2 rabbit serum (Pre; 1/1000). E. coliB) Proteins were detected with either commercial 
anti-M1 antibody (commercial; 1/5000); or anti-M1 rabbit serum at different dilutions.  M – Molecular 
marker; -ve – Plants infiltrated with empty pRIC vector. Arrows indicate the position of the respective 
proteins (± 17 kDa M2, ± 30 kDa 5xM2e-HAtrans and ± 27 kDa M1). 
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final test was carried out using an enzyme-linked immunosorbent assay (ELISA) as described in 
section 2.2.8.  
Figure 8| Testing of rabbit sera using indirect ELISA. (A) Indirect ELISA of anti-M2 rabbit sera at               
1/50 dilution using either the plant produced 5xM2e-HAtrans and M1 (negative control) proteins or the 
synthetic M2e peptide (Genscript, China) as coating antigens. The commercial antibody 14C2 was used 
at a 1/5000 dilution as positive control to confirm the presence of recombinant proteins. (B) Indirect 
ELISA of anti-M1 rabbit sera at different dilutions using either the plant produced M1 or 5xM2e-HAtrans 
(negative control) proteins as coating antigens. (C) Reciprocal dilution values of the M1 rabbit sera 
collected after each bleed to validate immune responses against M1. The markers indicate the mean 
value of triplicate samples and error bars indicate the standard error of the mean (*p< 0.001). 
A) B) 
C) 
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Because bacterial-produced proteins gave high signal background on western blots with the 
rabbit serum, proteins expressed in plants instead of bacteria were used as coating antigens for 
ELISAs.  
To probe for M2 specific antibodies in the M2 rabbit sera, plates were coated with either the 
plant-produced 5xM2e-HAtrans protein or with a synthetic M2e peptide as positive controls. The 
plant-produced M1 was used as a negative control. As shown in Figure 8A, detecting 5xM2e-
HAtrans with a 1/5000 dilution of the commercial 14C2 monoclonal antibody serum resulted in 
a significant increase in absorbance compared to the M1 protein (negative control). However, 
when the rabbit serum was used, no differences in absorbance could be detected between the 
5xM2e-HAtrans fusion protein, the M2e synthetic peptide or the M1 protein. Serial dilutions of 
the M2 serum lead to the same results (data not shown).  
To test the M1 rabbit sera for M1-specific antibodies, ELISA plates were coated either with plant-
produced M1 (positive control) or 5xM2e-HAtrans (negative control), and the absorbances 
compared. Detection of plant proteins with a 1/50 dilution of the anti-M1 rabbit serum resulted 
in an absorbance around 1.37 for wells coated with M1, whereas for wells coated with the 
negative control (5xM2e-HAtrans) the absorbance was around 0.11. This significant difference 
was also observed at a smaller scale, (0.77 for M1 and 0.18 for 5xM2e-HAtrans) when the serum 
was diluted by 100-fold (Figure 8B).  
To evaluate the increase in anti-M1 specific antibodies in the rabbit serum after each injection, 
titration values were calculated for the pre-bleed (day 0), first boost (day 14), second boost (day 
21), and final bleed (day 42) (Figure 8C). As it can be observed, the anti-M1 specific antibody 
concentration steadily increased after each boost, reaching a reciprocal endpoint titer value 
around 450 (Figure 8C). 
2.4. Discussion 
In this section of the study, I set out to produce antibodies against the two matrix proteins           
(M1 and M2) from Influenzavirus A, because current commercial antibodies against these 
proteins are exceedingly expensive, especially for ELISA applications. To create these antibodies, 
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the two proteins had to be produced in high amounts and in relatively short time. An E. coli based 
system was used for this effect due to its ease of manipulation and relatively short production 
times (Chen 2012; Terpe 2006; Rosano & Ceccarelli 2014).  
Initial trials for M2 expression in E. coli using Luria Broth media were successful although 
expression levels were relatively low and the protein was found completely in the insoluble 
fractions. Previous studies have shown that exogenous expression of the M2 protein in bacteria 
resulted in decreased host cell viability (Prasetyoputri et al. 2010). I also reported a decrease in 
the OD600 of recombinant bacteria expressing M2 as soon as they were induced with IPTG 
suggesting that M2 might somehow be harmful to the bacterial cells. These results are consistent 
with previous studies which demonstrated that recombinant M2 is able to permeabilize cell 
membranes, causing cell lysis (Frace et al. 1999; Guinea & Carrasco 1994). M2 is a membrane-
bound protein that acts as a proton pump in native influenza virions; its transmembrane portion 
contains highly hydrophobic amino acids which have been previously reported to compromise 
M2 solubility and yields in prokaryotic and eukaryotic cell systems (Frace et al. 1999; Czabotar et 
al. 2004; Mitraki et al. 1991).  Some studies have even reported that efficient expression of M2 
in recombinant cells can only be obtained in the presence of its target inhibitor, amantadine 
(Black et al. 1993).  
In light of these constraints, I set to carry out different strategies to try increase the amounts of 
protein without killing the bacteria; these included: lower incubation temperatures, lower 
concentration of the inducer (IPTG), longer induction periods and different induction media 
(Khow & Suntrarachun 2012). Although inoculating the bacteria at a lower temperature                 
(i.e. 28 oC) and for longer periods (i.e. 16 hrs), did reduce bacterial cell death while increasing 
protein levels, the most efficacious strategy was undeniably when bacteria were grown on the 
highly enriched media, Terrific broth. Terrific Broth, developed by Tartoff and Hobbs (1987), has 
been shown to increase bacterial growth and plasmid yields while slowing cell lysis (Tartof & 
Hobbs 1987; Collins et al. 2002; Collins et al. 2013). It contains high levels of tryptone, yeast 
extract and glycerol which provide amino acids, and carbohydrates necessary for high density 
growth. It also contains potassium phosphate which maintains optimal pH during growth.       
When induced on TB media, I observed a significant increase in recombinant M2 expression levels 
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compared to the traditional LB media. This increase was also accompanied by a reduction in cell 
death in TB induced cells. This effect has been demonstrated by several previous studies that 
used TB to express different proteins in E. coli (Manderson et al. 2006; Lim et al. 2000).                
What I did not anticipate was the appearance of low levels of soluble M2 in TB-induced cells.      
As previously discussed, M2 is an intrinsic membrane-bound protein and should therefore be 
insoluble. I suspect that the presence of glycerol in the TB media must have prevented 
“unfavorable” hydrophobic interactions in the M2 protein. It has previously been described that 
the addition of certain polyols (such as glycerol) to the incubation media can enhance the stability 
and solubility of membrane proteins in solution (Yasui et al. 2010). To the best of my knowledge, 
this is the first time that the full-length influenza A M2 protein has been expressed in E. coli in a 
soluble form without the addition of detergents.  
M1 preliminary expression trials showed high levels of expression using LB which is in conformity 
with previous studies (Syed et al. 2012; Guo et al. 2009). Expression of full-length M1 with pPROEx 
yielded detectable protein levels in both soluble and insoluble fractions of induced E. coli cells, 
as determined by anti-His immunoblot. It is important to note that despite several attempts to 
try increase the solubility of M1 (by varying IPTG concentrations, induction media, incubation 
temperatures and durations), the insoluble fraction always showed significantly higher levels of 
protein compared to the soluble fraction; more interestingly, the presence of M1 multimers 
could only be observed in the insoluble fraction.  
In its native environment, the influenza A M1 protein forms a coat inside the viral membrane 
envelope that maintains the structural integrity of the virion and encapsidates the viral genome 
complexed with the NP (vRNP). For this, the M1 protein is able to bind both vRNP and viral 
membrane envelope simultaneously (Ruigrok et al. 2000). Although the exact mechanisms of the 
M1 and lipid membrane binding are not fully understood, a recent study has showed that M1 
dimerization is enhanced by the presence of lipid membranes and that once bound to the 
membrane, M1 dimers recruit additional M1 in solution to form large complexes at the surface 
of the membrane (Hilsch et al. 2014). Based on these findings, I can hypothesize that both the 
increased levels of M1 and the exclusive presence of multimers observed in the insoluble fraction 
can be in part explained by the membrane-binding properties of M1. I say “in part” because most 
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certainly, overexpression of the non-native M1 protein in E. coli also has a role in directing 
recombinant protein to inclusion bodies (i.e. insoluble fraction).  
Since the highest amount of protein in both M1 and M2 trials was observed in inclusion bodies, I 
decided to proceed with these for rabbit inoculations. Inclusion bodies in E. coli are usually 
formed because of a defense mechanism that protect the cell when heterologous protein is 
overexpressed. If the expression levels of a non-native protein goes beyond 2 % of the total 
cellular proteins, it generally leads to inclusion body formation (Mitraki et al. 1991). Other factors 
such as hydrophobic regions, misfolding or disulfide bonds are also believed to play a role in 
inclusion body formation (Singh et al. 2015).  
These inclusion bodies have been long considered as a waste product composed of non-active 
misfolded protein aggregates that were too time-consuming and cumbersome to solubilize 
(García-Fruitós 2010). However, recent studies on the formation and composition of inclusion 
bodies have shed light on new evidence that IBs, contrarily to what had been widely believed, 
are at least in part composed of biologically active proteins. This was first demonstrated when 
the green fluorescent protein (GFP) was shown to be highly fluorescent inside inclusion bodies 
(García-Fruitós et al. 2005) and later supported by other studies using different proteins that 
were also found to be active inside inclusion bodies (Morell et al. 2008; Huang et al. 2013; 
Jevsevar et al. 2005). Thus, combining these new findings with already known advantages from 
IBs (i.e. expression of a very high level of protein; easy purification of the inclusion bodies from 
cells; lower degradation of the expressed protein; resistance to cellular proteases; and lack of 
contaminants/high purity), researchers are now looking at IBs less as a “dead-end” by-product 
but more like “highly pure deposits of recombinant protein” (Huang et al. 2013; Singh & Panda 
2005; García-Fruitós 2010). In agreement with this and in perspective with my work, a recent 
study has demonstrated that inclusion bodies containing the desired recombinant protein can be 
used as antigens to directly immunize animals and obtain polyclonal serum (Yang et al. 2011). 
Therefore, it was decided to partially purify M1 and M2-containing IBs from E. coli using 
successive washes in PBS which were then injected into rabbits for antibody production.       
Rabbits are the most widely used animal for antibody production because of its convenient size, 
ease of handling and large amounts of serum producing adequate volumes of high-titer antisera 
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(Stills et al. 2012; Hanly et al. 1995). Incomplete Freunds’ adjuvant was used at a 1:1 ratio with 
the protein. This adjuvant is routinely used in polyclonal antibody production in animals and has 
been widely demonstrated to be efficient in improving the immune response to an antigen 
(Leenaars & Hendriksen 2005; Hanly et al. 1995).  
Two weeks after the final injection, collected serum was used on immunoblots loaded with either 
bacterial or plant produced recombinant M2 and M1 proteins. Between the two sera used, only 
the anti-M1 serum showed visible results that confirmed detection of the M1 protein. This was 
observed for both bacterial and plant produced proteins, indicating that the serum was reactive 
against soluble and insoluble proteins. Moreover, since the plant proteins did not contain a 
Histidine tag, it can be assumed that the antibodies present in the serum were specific to M1. 
There was however, excessive background signal, especially when using the M2 serum. This was 
probably linked to the presence of non-specific antibodies in the serum, reactive to host proteins. 
Pre-absorption of the sera against proteins from untransformed E. coli cell lysate has been 
suggested to decrease background. However, in this case it did not improve band visualization 
(data not shown).  
To confirm the presence (or absence) of specific antibodies, sera was used to detect plates coated 
with plant-produced proteins in an indirect ELISA test, as ELISAs are generally more specific and 
qualitative than immunoblots. Moreover, since the proteins used to coat the ELISA plates were 
made in plants, the background signal should be minimized.  
To detect the M2 serum, a fusion protein presenting five tandem copies of the M2 extracellular 
domain was used (5xM2e-HAtrans; full details explained in Chapter 3). This was chosen as it was 
never possible to express the full M2 protein in plants and E. coli-produced M2 would give too 
much background. Nonetheless, since the antibodies desired had to detect the M2e domain for 
the continuity of the project, it should not pose an issue. A positive control was included using a 
commercial anti-M2 antibody (14C2) to exclude the possibility of protein degradation in the 
samples. As previously for immunoblots, ELISA experiments using the M2 serum did not show 
any increase in activity compared to negative samples. This indicates that either i) there were no 
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specific M2 antibodies in the serum or ii) the levels of specific M2 antibodies were too low to be 
detectable.  
On the other hand, the M1 serum was able to react with plant M1. The antibody titration values 
showed a reciprocal endpoint titre around 450, although this value could be higher as no further 
dilutions were tried. M1-specific antibody levels seemed to increase after each boost, with the 
strongest values after the third immunization; this confirmed that the M1 protein efficiently 
induced rabbit immune responses.  
Overall, by combining the immunoblotting and the ELISA results, I can conclude that between the 
two serums, only the M1 showed detectable levels of specific antibodies. 
2.5. Conclusions 
To summarize, Influenzavirus A M1 and M2 proteins were successfully expressed in E. coli, mostly 
in the form of insoluble inclusion bodies. In contrast to M1, which expressed at high levels in 
conventional LB media, M2 was only produced in low amounts and its expression had to be 
optimized. After several trials, the best M2 expression was obtained by growing recombinant 
bacteria in the enriched TB media for longer periods (i.e. 16 hrs) and at lower temperatures (i.e. 
28 oC). Inclusion bodies containing M1 or M2 were then partially purified by successive washes 
in PBS and injected into rabbits to raise antibodies.  
The anti-M1 serum could detect M1 protein produced in bacteria or plants as shown by 
immunoblot and ELISA experiments. This serum can be used for subsequent immunoblots and 
ELISA experiments, thus reducing greatly the costs of the project. 
The anti-M2 serum, on the other hand, was never shown to react with any of bacterial M2, plant 
5xM2e-HAtrans or with a synthetic M2e peptide. It seemed that the levels of anti-M2 antibodies 
in the serum were too low for detection. It could be possible that the M2 epitopes were obscured 
by other proteins in the insoluble bodies that made them inaccessible to the rabbits’ immune 
system. There have been reports showing that the M2 protein is a poor immunogen and that M2-
specific antibody responses remained low in the mammalian host (Deng et al. 2015). However, 
these reports were made after natural or experimental infection with influenza A viruses, never 
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after injection of a solution containing recombinant M2. In fact, most of the literature regarding 
the production of M2 serum for experimental analysis has used the M2e peptide as an 
immunization antigen, not the full M2 protein (Mardanova et al. 2015; Nikbakht et al. 2012; De 
Filette et al. 2011). Here I have shown that recombinant M2 produced in E. coli using the 
conditions described above, was not able to elicit detectable anti-M2 antibodies in the serum of 
injected rabbits. Nevertheless, I hypothesize that by increasing the amounts and the purity of 
recombinant M2 as well as the number and the time between each boost, should result in 
increased immune responses against the M2 protein. Feng et al. 2006 stated that although M2 
induces poor immune responses, “primary infections elicit a degree of B cell immune memory 
against M2e that can be boosted by subsequent challenges”. Due to time and cost constrains, I 
was not able to repeat immunization trials, but further trials must be conducted to verify these 
hypotheses.  
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Chapter 3: Design and optimization of several M2e-HA chimaeric 
protein expression in N. benthamiana 
3.1. Introduction 
Influenza has been infecting humans for many centuries and continues to be today one of the 
leading causes of human acute respiratory infections (Mayor 2010). With a global annual attack 
rate estimated at 5 - 10 % in adults and 20 - 30 % in children, which leads to more than 4 million 
severe infection cases and 250,000 - 500,000 deaths worldwide, researchers have ranked 
influenza  (among other types of respiratory diseases) to be the fourth leading cause of death in 
the world (Anon 2014; Lozano et al. 2012). As a result, influenza vaccine development has been 
a priority for international health authorities.  
Despite the reported efficacy of existing approved seasonal influenza vaccines (Foppa et al. 2015; 
Jefferson et al. 2014), long production times, limited capacity and the lack of broadly cross-
protective immune responses have made it difficult for current vaccines to meet the global 
demand (Lee et al. 2014; Doherty & Kelso 2008; Shoji et al. 2008).  
To address this point, alternative approaches to influenza vaccine formulations and production 
systems are being examined. To produce vaccines with broad efficacy, researchers have been 
targeting conserved epitopes that exist across different influenza virus subtypes. To this date, the 
most promising epitopes investigated are the M2e ectopic peptide and the HA stalk domain (de 
Vries et al. 2015; Doherty & Kelso 2008; Gerhard et al. 2006; Fiers et al. 2009; Yassine et al. 2015). 
However, given the low immunogenicity of these peptides in their native conformation, the 
challenge now relies on finding ways of increasing the immunogenicity of these conserved 
sequences. VLPs have shown promising results for presenting influenza surface proteins in a 
highly immunogenic form (Choi et al. 2013; D’Aoust et al. 2010; Kang et al. 2012; Song, Van 
Rooijen, et al. 2011). VLPs are generated upon expression and subsequent self-assembly of 
defined recombinant viral proteins. These nanoparticles present an external surface resembling 
that of their native virus with the benefit of not incorporating viral genomic material, making 
them safer than inactivated viral vaccines (Pêra et al. 2015). The presentation of antigens in a 
native conformation has been shown to achieve enhanced stimulation of humoral and cellular 
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immune responses (Lee et al. 2014; Kang et al. 2012). This is particularly true in the case of 
enveloped viruses, since enveloped VLPs should present the surface antigens in their natural 
membrane-bound state (Grgacic & Anderson 2006). VLPs have been produced using a variety of 
systems including insect cells (Choi et al. 2013), microbial cells (Denis et al. 2008), mammalian 
cells (Steel et al. 2010) and more recently, in plants (D’Aoust et al. 2010; Pillet et al. 2015). 
For the last two decades, plant-based platforms have been gaining popularity as an important 
alternative to “conventional” fermenter-based systems for recombinant protein production. 
Major advantages supporting plants as bioreactors include, lower up-front investment required 
for commercial production, no risk of contamination with animal pathogens and high scalability 
potential (Sainsbury & Lomonossoff 2014; Thuenemann et al. 2013; Waheed et al. 2016).  
Initially, modification of plants for recombinant protein expression relied on the generation of 
stable transgenic lines, which is both time-consuming and resource-intensive (Sainsbury & 
Lomonossoff 2014). However, with the development of new transient expression methods, it is 
now possible to produce commercially-relevant levels of recombinant proteins within days 
versus several months using stable transformation (D’Aoust et al. 2010). These recent advances 
in plant biopharming have made plants an excellent alternative to current egg-based platforms 
for influenza vaccine production. 
The aim of the work presented here was to design HA-based M2e-containing chimaeric proteins 
with the potential to self-assemble into M2e-presenting VLPs in plants. It is still almost impossible 
to predict whether chimaeric proteins will be compatible with VLP assembly or whether they will 
be immunogenic in the resulting chimaeric VLP. And, although Kim, Lee, et al. (2013)  
demonstrated that immunogenic VLPs could be obtained in insect cells by fusing 5xM2e to the 
transmembrane domain of HA, differences in expression systems and protein sequences used 
between this and their study, make it difficult to extrapolate on VLP formation. Hence, to 
maximize the chances of obtaining immunogenic VLPs, I designed different M2e-HA fusions (see 
Figure 1).  
The first variation involved fusing the M2e peptides to either the full HA stalk domain (5xM2e-
HAstalk) or just the transmembrane domain (5xM2e-HAtrans). Besides having possible structural 
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properties that could enhance VLP formation, the HA stalk domain is extremely well conserved. 
In fact, apart from the M2e peptide, the HA stalk domain has been the most used peptide for the 
generation of candidate universal influenza vaccines (Staneková et al. 2011). Hence, by including 
the stalk domain in our M2e fusions, it could be possible to create VLPs that have increased cross-
protection as compared to VLPs with only the HA transmembrane domain.  
The second permutation of the M2e-HA fusions involved the addition of the tetramerizing 
domain of the yeast transcription factor, general control nondepressible 4 (GCN4). The idea of 
using GCN4 as a tetramerizing scaffold originated from a study conducted by De Filette et al. 
(2008), where the M2e peptide was fused to GCN4 (M2e-tGCN4) to obtain a structure that would 
closely mimic the tetrameric conformation of the native M2e peptide. Antibodies raised by M2e-
tGCN4 immunization were shown to specifically bind to the surface of influenza-infected cells 
and to an M2-expressing cell line. Here, the incorporation of GCN4 into the M2e-HA chimaeras 
was investigated as a way to possibly enhance immunogenic responses against the M2e peptides. 
Introducing a tetramerizing domain might not be compatible with the natural trimerization 
induced by the HA stalk, therefore, two control constructs were created were the GCN4 domain 
was not added.   
Finally, the last permutation of the M2e-HA fusions involved using only one copy of the M2e 
peptide (1xM2e-HAtrans and 1xM2e-HAstalk) instead of five. These constructs would allow to 
test whether multiple tandem copies of M2e in a vaccine construct would elicit higher M2e IgG 
titers than one M2e containing construct, as suggested by Deng et al. (2015).  
In total, six different M2e-HA chimaeras were created: 5xM2e-GCN4-HAstalk, 5xM2e-GCN4-
HAtrans, 5xM2e-HAstalk, 5xM2e-HAtrans, 1xM2e-HAstalk and 1xM2e-HAtrans. Injection agro-
infiltration was used for the rapid optimisation of protein expression and several methods were 
analyzed to maximize yields in plants. Finally, most promising M2e-HA fusion proteins were 
selected for co-expression studies with the influenza matrix protein 1. This optimization work is 
the initial step towards creating the first plant-produced influenza VLP vaccine based on M2e-HA 
chimaeric proteins.  
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3.2. Methods 
3.2.1. Fusion protein design 
M2e alignment was performed using CLC Bio (Qiagen); a full list of the sequences used can be 
found in Appendix A. The gene construct for encoding the 5xM2e-GCN4-HAstalk fusion protein 
was genetically designed to contain the HA signal peptide (MEKIVLLFAIVSLVKS-  
A/Vietnam/1203/04, H5), five copies of different M2e sequences from the M2e consensus 
(SLLTEVETPTRNEWECRCSDSSD), human type (SLLTEVETPIRNEWGSRSNDSSD, (Kim, Lee, et al. 
2013)), swine type (SLLTEVETPTRSEWESRSSDSSD, A/California/4/2009, H1N1), and two avian 
types (SLLTEVETPTRNEWESRSSDSSD, A/Vietnam/1203/04,H5N1 and 
SLLTEVETLTRNGWGCRCSDSSD, A/Hong Kong/156/97, H5N1) separated by a EAAAK linker 
peptide, a tetramerizing leucine zipper derived from GCN4 (De Filette et al., 2008), and the stalk, 
transmembrane and cytoplasmic domains of HA derived from A/Vietnam/1203/04, H5N1. 
Human codon optimized 5xM2e-GCN4-HAstalk fusion protein sequence was synthesized by 
Genscript (China) and delivered in the pUC57 vector.  
The pUC57-5xM2e-GCN4-HAstalk vector was transformed into DH5-α (E. cloni™, Lucigen) and 
Dam- (devoid of dam methylation) (BIO 85044, Bioline, Meridian Bioscience Inc., USA) chemically 
competent E. coli cells according to the method described by Sambrook et al. (1989).  
The transformed cells were plated on Luria Bertani (LB) media agar plates (10 g Tryptone, 5 g 
Yeast Extract, 5 g NaCl in 1 L water; 15 g of Bacterial Agar was added for agar plates) 
supplemented with ampicillin (amp) (100 μg/mL). Plates were incubated at 37 °C, O/N. Single 
colonies were selected and inoculated in 10 mL LB broth supplemented with 50 μg/mL ampicillin 
and incubated with agitation for 16 hrs at 37 °C.  
Plasmid isolations were performed using the QIAprep® Spin Miniprep kit (Qiagen) according to 
instructions provided by the manufacturer. Recombinant pUC57-5xM2e-GCN4-HAstalk clones 
were verified by restriction enzyme digestion. Recombinant DNA (~ 500 ng) was digested for 1 hr 
at 37 °C using 1 U XhoI and 1 U BamHI (Thermo Fisher Scientific, MA, USA) per reaction according 
to the manufacturer’s instructions.  Linearized DNA was separated on 1 % w/v TBE (89 mM Tris 
base, 89 mM boric acid and 2 mM EDTA [pH 8]) agarose gels containing 0.5 mg/mL ethidium 
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bromide. O’GeneRuler™ 1kb DNA ladder #SM1163 (Thermo Fisher Scientific, MA, USA) was used 
as molecular weight marker on all the agarose gels. 
After verification of pUC57-5xM2e-GCN4-HAstalk in both DH5-α and Dam- cells, several 
restriction digests were performed to create five different permutations of 5xM2e-GCN4-
HAstalk, as illustrated in Figure 1.   
Briefly, recombinant DNA (~ 1000 ng) from DH5-α was digested using 1 U of either BamHI and 
BglII or XbaI and NheI to produce 1xM2e-HAstalk or 5xM2e-HAstalk respectively.                               
DNA from Dam- cells (not methylated) was digested with 1 U of either BclI and BglII or BamHI 
and BclI to produce, 5xM2e-GCN4-HAtrans or 1xM2e-HAtrans respectively. All digests were 
performed for 1 hr at 37 °C. However, BclI / BglII and BamHI / BclI had to be first digested for 1 
hr at 37 °C without BclI, followed by heat inactivation for 20 min at 80 °C. Only after inactivation, 
BclI was added to the reactions and incubated at its optimal temperature of 55°C for 1 hr. 
Digested DNA was separated on 1 % w/v TBE agarose gels containing 0.5 mg/mL ethidium 
bromide and visualized under long wavelength ultraviolet (UV) illumination. Corresponding 
bands were identified and DNA was purified from the agarose gels using the QIAquick® Gel 
Extraction kit (Qiagen) following the manufacturer’s instructions. Purified DNA was re-
circularized with T4 DNA Ligase (Thermo Fisher Scientific, MA, USA) for 15 min at room 
temperature, per manufacturer’s instructions and transformed into DH5-α as previously. pUC57-
5xM2e-HAstalk was also transformed into Dam- cells. All transformed cells were plated on Luria 
Bertani (LB) media agar plates supplemented with ampicillin (100 μg/mL).  
Positive colonies were selected by colony PCR using gene-specific primers as showed in Table 1. 
The PCR reactions of the appropriate template DNA consisted of 250 μM dNTPs, 0.2 μM of each 
primer, 1 x Kapa taq Buffer A and 0.5 units (U) KAPA Taq DNA Polymerase (KAPA Biosystems).  
The reactions were amplified with an initial denaturation step at 92 °C for 2 min and 30 s; 
followed by twenty-five cycles of denaturation at 92 °C for 30 s, annealing at 47 °C for 30 s and 
elongation at 72 °C for 90 s. Reactions finished with a final elongation step at 72 °C for 4 min. 
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Figure 1| M2e-HA fusion protein design. Restriction enzyme digest strategy used to create the six different M2e-HA permutations as 
described in section 3.2.1. SP – Haemagglutinin signal peptide; C – consensus M2e sequence; H – M2e from human type (Kim, Lee, et 
al. 2013); S – M2e from swine type (A/California/4/2009, H1N1); A I – M2e from avian type (A/Vietnam/1203/ 04, H5N1); A II – M2e 
from avian type (A/Hong Kong/156/97, H5N1);  – EAAAK linker; GCN4 – Leucine zipper of the yeast transcription factor GCN4 
(oligomerization domain, 105 bp); HA2 – Haemagglutinin stalk domain; TM/CT – Haemagglutinin transmembrane and cytoplasmic 
domain. Figure not made to scale.  
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Positive Dam- colonies containing pUC57-5xM2e-HAstalk were inoculated into 10 mL LB 
broth supplemented with 50 μg/mL ampicillin and incubated with agitation for 16 hrs at 
37 °C. Plasmid isolation was performed as previously described. Recombinant DNA          
(~ 1000 ng) was then digested for 1 hr at 37 °C, with BclI and BglII to create the last 
chimaeric protein: 5xM2e-HAtrans.  
Digested DNA was then separated on a 0,8 % w/v TBE agarose gel and the corresponding 
band was purified and re-circularized as indicated previously. Re-circularized            
pUC57-5xM2e-HAtrans was then transformed into DH5-α cells as previously. Positive 
clones were identified by colony PCR using the same gene-specific primers (Table 1) and 
conditions as previously described.  
After verification of every clone by colony PCR, the plasmid DNA was sequenced 
(Macrogen Inc., Netherlands) using the gene-specific primers (Table 1). Sequencing data 
was analyzed using CLC MAIN WORKBENCH (Qiagen®).  
3.2.2. Sub-cloning of fusion proteins into different plant expression vectors   
All fusion proteins were designed with AgeI and NcoI sites on the 5’end and an XhoI site 
on the 3’ end to facilitate cloning into three different plant expression vectors (designed 
to target recombinant proteins to the cytosol): pTRAc, pRIC 3.0 and pEAQ-HT.                   
The M1 sequence described in Chapter 1 was also used for plant expression since it 
contained an AgeI and AflIII site on the 5’end and an XhoI site at the 3’end. pTRAc was 
kindly provided by Dr Rainer Fischer, Fraunhofer Institute, Aachen, Germany. pRIC 3.0  
is a novel autonomously replicating plant expression vector developed using elements 
of the replication machinery of Bean Yellow Dwarf Virus as described by Regnard et al. 
(2010). pEAQ-HT contains a P19 silencing suppressor and the 5’/3’-untranslated region 
(UTR) from the Cowpea mosaic virus (CPMV) RNA-2 which has been shown to greatly 
Table 1| Primers for plant expression 
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enhance the translation efficiency of recombinant proteins (Sainsbury & Lomonossoff, 
2008). The M1 and fusion protein sequences were excised from the pUC57 backbone by 
first digesting the plasmid DNA with XhoI and either NcoI (or AflIII for M1) or AgeI for      
1 hr at 37 °C, after which the DNA was gel-purified with the QIAquick® Gel Extraction kit 
(Qiagen). This digestion yielded recombinant proteins with 5’ AgeI (for cloning into 
pEAQ-HT) or NcoI (for cloning into pTRAc and pRIC 3.0) sites and 3’ XhoI sites. 
The pTRAc and pRIC 3.0 expression vectors were linearized by restriction digestion with 
AflIII and XhoI whereas pEAQ-HT was linearized with AgeI and XhoI. The vector DNA was 
dephosphorylated using 1 U rapid alkaline phosphatase (Roche) per the manufacturer’s 
instructions. 
Recombinant protein sequences were then directionally sub-cloned into all three 
expression vectors according to their respective restriction sites using T4 DNA Ligase 
(Thermo Fisher Scientific, MA, USA). All constructs are listed in Table 2.  
Recombinant clones were transformed into DH5-α chemically competent E. coli cells (E. 
cloni™, Lucigen) as described by Sambrook et al. (1989). Transformed cells were plated 
on LB media plates supplemented with ampicillin (100 μg/mL) O/N at 37 °C. Positive 
Table 2|Different expression vectors and recombinant proteins that were tested 
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clones were selected by colony PCR using the same settings and gene-specific primers 
(Table 1) as previously. 
3.2.3. Agrobacterium transformation 
A. tumefaciens LBA4404 and A. tumefaciens GV3101::pMP90RK cells were made 
electrocompetent using the method described by Shen and Forde (1989).  The pEAQ-HT 
or pTRAc and pRIC 3.0 recombinant plasmids were electroporated into A. tumefaciens 
LBA4404 or A. tumefaciens GV3101::pMP90RK, respectively.  Transformation of the A. 
tumefaciens strains was carried out by electroporation according to the method 
described by Maclean et al. 2007. Briefly, 200 to 400 ng of recombinant plasmid DNA 
was added to a 1 mm chilled electroporation cuvette (Bio-Rad, CA, United States of 
America), along with 100 µl of electrocompetent cells. After 5 minutes of incubation on 
ice, cells were electroporated using a Bio-Rad GenePulser™ under the following 
conditions: 1.8 kV, 25 µF, 200 Ω. After electroporation, 900 µl of antibiotic-free Luria 
broth was added to the electroporated cells, which were incubated for 2 hrs at 27 °C. 
Recombinant pEAQ-HT clones were selected on LB media agar plates at 27 °C containing 
30 μg/mL kanamycin and 50 μg/mL rifampicin.  The pTRAc and pRIC 3.0 clones were 
selected under the same conditions except that the plates were additionally 
supplemented with 50 μg/mL carbenicillin.  Successful transformation was confirmed by 
colony PCR (as in Section 2.2.1) using the gene-specific primers listed in Table 1. 
3.2.4. A. tumefaciens-mediated transient expression 
Starter cultures of recombinant pEAQ-HT, pTRAc and pRIC 3.0 A. tumefaciens cells, 
including A. tumefaciens LBA4404 containing pBIN-NSs, the plasmid carrying the TSWV 
NSs silencing suppressor gene, were supplemented with the relevant antibiotics and 
grown in LB broth as described by Maclean et al. (2007).  To prevent clumping of the 
recombinant LBA4404 A. tumefaciens cells, the medium was supplemented with 2 mM 
magnesium sulphate (MgSO4).    
After making glycerol stocks, the starter cultures were used to inoculate induction 
medium (Maclean et al., 2007) with the addition of the appropriate antibiotics, including 
20 μM acetosyringone. The cultures were incubated O/N at 27 °C with agitation to 
induce expression of the vir genes. The cells were harvested from the O/N cultures by 
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centrifugation at 4 000 x g for 5 min and re-suspended in infiltration medium (10 mM 
magnesium chloride [MgCl2], 10 mM 2-morpholinoethanesulfonic acid [MES],                  
3% sucrose and 150 μM acetosyringone in water, pH 5.6).  The cell suspensions were 
incubated at 22 °C for 2 hrs to allow for additional expression of the vir genes prior to 
infiltration. After incubation, the cultures were diluted to the required optical density 
(OD600) in infiltration medium. The cell densities (OD600) used for infiltration of the 
constructs were varied to find the optimal cell concentration where all recombinant 
proteins were successfully co-expressed. 
For each one of the expression vectors used, the relevant recombinant A. tumefaciens 
constructs were infiltrated into six-week-old N. benthamiana leaves as described by 
Maclean et al., 2007.  N. benthamiana plants were grown from seed in a controlled plant 
growth room. The plants were grown at 22 °C, with 16 hrs of light per day for 6 weeks.  
Small-scale infiltration was performed by injecting the Agrobacterium suspension into 
the abaxial spaces of the plant leaves, using a 1 mL needless syringe. After infiltration, 
the plants were grown at 22 °C under 16 hrs/8 hrs light/dark cycles until harvested.    
As a negative control the plants were infiltrated with infiltration medium.                       
Time-trials were conducted to evaluate and compare single and co-expression of fusion 
proteins with M1 in different vectors.   
3.2.5. Crude leaf extract 
For protein extraction, three leaf discs (cut by using the cap of a microcentrifuge tube) 
were harvested at desired days post infiltration (dpi). Leaves were then ground up using 
a micro-pestle in the presence of extraction buffer at an approximate ratio of                      
1:3 (weight: volume). Extraction buffer was composed of 1xPBS (PBS composition:        
137 mM NaCl, 1.8 mM KH2PO4, 10 mM Na2HPO4, 2.7 mM KCl, pH 7.4) containing 
protease inhibitor (cOmplete, Mini, EDTA-free tablets, Roche) as specified.  
Ground leaf extracts were clarified by a centrifugation step at 15,000 x g for 10 min. The 
supernatant representing the crude leaf extract was collected for further analysis.  
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Crude leaf extracts were incubated at 90 °C for 10 min in sample application buffer 
prepared for analysis by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS PAGE) (Sambrook et al., 1989) and stored at -20 °C until further analysis. 
3.2.6. Coomassie Stained SDS PAGE gels and western blots 
Recombinant proteins were resolved on 10 % SDS polyacrylamide gels, loading an equal 
volume of plant extract into each lane to separate proteins on the basis of their 
molecular weights (Sambrook et al. 1989). To determine the sizes of the resolved 
proteins in Coomassie stained gels and on nitrocellulose membranes, a Color Protein 
Standard Broad Range Ladder #P7712S (New England Biolabs, USA) was used as a 
molecular weight marker. 
For Coomassie, gels were stained with Coomassie Brilliant Blue R250 (Merck, Darmstadt, 
Germany) stain for 2 hrs at 37 °C and destained overnight with destain solution                  
(45 % methanol, 45 % water, 10 % glacial acetic acid).  
For western blots, gels and nitrocellulose membranes were pre-equilibrated for 10 min 
in transfer buffer (5.82 g Tris base, 2.93 g Glycine, 200 mL methanol in 1 L water, pH 9.2) 
before being transferred to a nitrocellulose membrane at 15 V for 90 minutes using a 
Trans-blot®SD semi-dry transfer cell (Bio-Rad, CA, USA). After electrophoretic transfer, 
the membranes were blocked in blocking buffer (5 % non-fat dairy milk and 1 x PBST       
(137 mM NaCl, 1.8 mM KH2PO4, 10 mM Na2HPO4, 2.7 mM KCl, pH 7.4 and                                
0.1 % Tween-20) for 30 min. The membranes were probed overnight at 4 °C with either 
1:10000 M1 rabbit serum, 1:5000 anti-M1 GA2B (Abcam, UK), 1:5000 anti-M2 14C2 
(Abcam, UK) or anti-histidine MCA 1396 mouse monoclonal IgG antibodies (ABD 
Serotec, Bio-Rad, CA, United States of America) diluted in blocking buffer. The 
membranes were then washed four times with blocking buffer for 15 minutes each and 
afterward incubated in a 1:10000 dilution of anti-mouse or anti-rabbit IgG (whole 
molecule) alkaline phosphatase conjugated antibody produced in goat (Sigma-Aldrich, 
Merck, Germany) in blocking buffer for 1 hr at 37 °C. Membranes incubated in secondary 
antibody were washed four times with 1 x PBST (without milk), with 15 min for each 
wash. Detection was performed with BCIP (KPL, MD, USA). Protein expression, 
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extraction and western blot analysis was repeated at least three times to confirm the 
expression of the recombinant influenza proteins.  
3.2.7. Analysis of post-translational modifications 
N-glycosylation sites of fusion proteins were predicted using the NetNGlyc 1.0 software 
available at URL http://www.cbs.dtu.dk/ services/NetNGlyc/. 
3.2.8. Indirect ELISA 
Indirect ELISA was used to compare fusion protein expression levels. 96-well Maxisorp® 
microtitre plates (Nunc) were coated with 100 μL/well of antigen diluted in coating 
buffer (10 mM Tris, pH 8.5). After incubating the plates O/N at 4°C, plates were blocked 
with TBS blocking buffer (5 % non-fat dry milk in 1 x TBS [50 mM Tris, 150 mM NaCl,      
pH 7.5]) for 2 hrs at RT after which they were washed four times with 1 x TST buffer                   
(1 x TBS [pH 7.5], 0.05 % Tween®20). The anti-M2 14C2 mouse monoclonal IgG antibody 
(Abcam, UK) was then diluted to 1:5000 in TBS and 100 μL was added to each well sera, 
after which plates were left for 1 hr at 37 °C for incubation. Blank wells containing no 
antibody were included as background control. After incubation, plates were washed 
four times with 1 x TST buffer and 100 μL of goat anti-mouse IgG alkaline phosphatase 
conjugate (1:10000, Sigma) diluted in blocking buffer was added per well and incubated 
for 1 hr at 37 °C. After incubation, the plates were washed four times with 1 x TBS (pH 
9) buffer and 200 μL SIGMAFAST™ p-Nitrophenyl phosphate (pNPP, Sigma) was added 
per well. The plates were developed in the dark for 30 min after which the absorbance 
was detected at 405 nm on a BIO-TEK® Powerwave XS microtitre plate reader. 
3.3. Results 
3.3.1. Designing the M2e constructs  
To cover a broader range of influenza A types and to increase the density of M2e 
epitopes, I designed a tandem repeat of five M2e sequences (5xM2e) derived from 
human, avian and swine origin influenza A viruses. In total, two avian-derived M2e 
sequences, one human, one swine and a consensus sequence derived from different 
species were used; all separated by a linker peptide (EAAAK). To determinate the 
consensus sequence (SLLTEVETPTRNEWECRCSDSSD), I aligned a total of 33 different 
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M2e sequences from several different Influenza A origins using the CLC bio software 
(Qiagen) (Figure 2).  
To present the 5xM2e repeats on the surface of VLPs, I originally designed a chimaeric 
protein (5xM2e-GCN4-HAstalk) by replacing the HA globular head with the 5xM2e 
repeats. Additionally, a domain known to stabilize oligomer formation (general control 
non-depressible 4, GCN4) was inserted between the C-terminal part of M2e5x and the 
N-terminal part of the HA stalk domain. From this original 5xM2e-GCN4-HAstalk 
sequence, I constructed five permutations (5xM2e-GCN4-HAtrans, 5xM2e-HAtrans, 
1xM2e-HAtrans, 5xM2e-HAstalk, 1xM2e-HAstalk), resulting in a total of six clones which 
were used to analyze the effect of each component on VLP formation and expression 
levels. A detailed structure of each construct can be found in Figure 1.  
3.3.2. Verification of M2e chimaera clones 
The M2e chimaeras, and the native M1 capsid protein were successfully cloned into the 
pTRAc-HT, pRIC 3.0 and pEAQ-HT plant expression vectors. These were then 
transformed into E. coli and subsequently into either A. tumefaciens GV3101::pMP90RK 
for pTRAc-HT and pRIC 3.0 or A. tumefaciens LBA4404 for the pEAQ-HT constructs. 
Figure 2 | M2e alignment of 33 sequences from different Influenza A strains.  
66 
 
Positive recombinant clones were screened by colony PCR using genes specific primers 
(Table 1). 
All constructs produced fragments of the expected size, confirming the presence of 
recombinant genes in pRIC 3.0 (figure 3), pEAQ-HT and pTRAc-HT (data not shown). To 
verify the integrity of sequence for each individual gene, recombinant clones were 
sequenced with gene-specific internal primers (Table 1). The sequences were analyzed 
in CLC bio (Qiagen) by multiple alignment of the sequence data with theoretical 
sequences of the plasmid.  Sequence analysis confirmed that the genes were intact and 
correct (data not shown). 
3.3.3. Small-scale optimisation of M2e chimaera expression in N. benthamiana 
The expression of every M2e chimaera in N. benthamiana was examined over 1 -  7 days 
post infiltration (dpi). Initial attempts were performed using the plant expression vector 
pTRAc-HT and an optical density of 0.5 for the recombinant Agrobacterium. Three 7 mm 
leaf disks per leaf were harvested and extraction was performed using 1 x PBS.            
EDTA-free protease inhibitor was added to PBS in initial trials, however its addition did 
Figure 3| Colony PCR to verify the presence of recombinant genes in pRIC 3.0. A) M2e-HA fusion 
constructs. Lanes: 1 - 5xM2e-GCN4-HAstalk [~ 1.3 kb]; 2 - 5xM2e-HAstalk [~ 1.2 kb]; 3 - 5xM2e-
HAtrans [~ 0.6 kb]; 4 - 5xM2e-GCN4-HAtrans [~ 0.7 kb]; 5 - 1xM2e-HAstalk [~ 0.8 kb]; 6 - 1xM2e-
HAtrans [~ 0.3 kb]. B) M1 colony PCR; M1 [~ 0.7 kb]. The molecular marker is represented by lanes 
M. 
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not improve significantly protein expression compared to PBS alone (data not shown). 
Hence, due to its high costs, protease inhibitor was not added throughout the remaining 
of the experiments. Total soluble protein was determined by Bradford assay. Expression 
levels were analyzed by western blotting, loading equal TSP amounts and using the 
monoclonal anti-M2 14C2 antibody which has been shown in previous studies to be able 
to bind to M2e epitopes. 
As shown in Figure 4, of all the fusion proteins, only the 5xM2e-HAstalk presented 
detectable levels of expression using the pTRAc-HT vector. This protein was readily 
detectable using the anti-M2 antibody, after only 3 days post-infiltration                       
(Figure 4, lane 1). Extracting proteins at days 5 and 7 resulted in decreased expression 
levels for 5xM2e-HAstalk, while the remaining proteins could never be detected (data 
not shown). Additional attempts of detection were tried using an anti-His antibody (the 
pTRAc-HT constructs add a Histidine tag on the N-terminus of the proteins). However, 
for all proteins, no difference could be observed between the anti-M2 and anti-His tag 
antibodies (data not shown).  
Considering these results, I decided to retry expression trials using two additional 
expression vectors: these were pRIC 3.0 and pEAQ-HT (Figure 5 and 6). Initial attempts 
using these vectors were performed with the same conditions as for the pTRAc-HT trials, 
Figure 4| Immunoblot of fusion protein expression in Nicotiana benthamiana using the pTRAc-HT 
expression vector. Infiltration was performed at OD600 0.5 and proteins were harvested at 3 d.p.i. and 
detected using the monoclonal anti-M2 antibody 14C2. +ve – M2 protein produced in E. coli; -ve – empty 
pTRAc-HT vector; M – Molecular marker; 1 – 5xM2e-HAstalk; 2 – 5xM2e-HAtrans; 3 – 5xM2e-GCN4-
HAstalk; 4 – 5xM2e-GCN4-HAtrans; 5 – 1xM2e-HAstalk; 6 – 1xM2e-HAtrans. 
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except that using an anti-histidine antibody was not possible for pRIC 3.0 and pEAQ-HT 
because these vectors did not provide a histidine tag.  
Overall, using the two new vectors, I could detect the expression of 4 out of six 
chimaeras, namely 5xM2e-GCN4-HAstalk, 5xM2e-GCN4-HAtrans, 5xM2e-HAtrans and 
5xM2e-HAstalk (Figure 5A and 6). Interestingly, all four proteins ran at higher molecular 
weights than what was predicted in silico. As showed in Table 3, an average of 10kDa 
increase was observed for both stalk fusions; whereas for the transmembrane fusions, 
the increase was slightly lower at about 7 - 8 kDa. Analysis of the M2e-HA fusion protein 
sequences using the NetNGlyc 1.0 program predicted three and two N-glycosylation 
sites for the fusions with and without the stalk domain, respectively. Moreover, 
although proteins were denatured prior to gel loading, 1 - 3 additional bands of higher 
molecular weight were detected for the constructs lacking the GCN4 domain (5xM2e-
HAtrans and 5xM2e-HAstalk), corresponding approximately to the double, triple and 
quadruple size of the original band (Figure 6, red arrows). This was observed to a lesser 
extent for the proteins that included the GCN4 domain (5xM2e-GCN4-HAtrans and 
5xM2e-GCN4-HAstalk) where only the dimer band could be clearly distinguished (Figure 
5, red arrows). The two remaining proteins, 1xM2e-HAtrans and 1xM2e-HAstalk could 
never be detected on immunoblots (Figure 5B). It is important to note that these two 
Table 3| Comparison between predicted versus observed recombinant protein sizes 
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proteins only contain one copy of the M2e peptide which could be too small for reliable 
detection with an anti-M2 antibody.  
In view of the inability to detect the 1xM2e-HAtrans and 1xM2e-HAstalk, it was decided 
to abandon further experiments involving these two proteins. Moreover, after further 
investigation into the chimaeric proteins containing the GCN4 domain, it was found that 
the sequence coding for GCN4 used in this project had several nucleotide changes that 
promoted the formation of dimers instead of tetramers (Figure 7). Therefore, because 
wild-type M2 protein forms tetramers and not dimers on the surface of native influenza 
Figure 5 | Immunoblot of 5xM2e-GCN4-HAstalk, 5xM2e-GCN4-HAtrans, 1xM2e-HAstalk and 
1xM2e-HAtrans expression in Nicotiana benthamiana using the pRIC 3.0 and pEAQ-HT 
expression vectors. A) Detection of 5xM2e-GCN4-HAstalk and 5xM2e-GCN4-HAtrans expression. 
B) Detection of 1xM2e-HAstalk and 1xM2e-HAtrans expression. Infiltration was performed at 
OD600 0.5 and proteins were harvested at 3 d.p.i. and detected using the monoclonal anti-M2 
antibody 14C2.  -ve pRIC/pEAQ – empty expression vectors; +ve – pRIC-5xM2e-GCN4-HAtrans; M 
– Molecular marker. Black arrow indicates the position of the respective protein; red arrows 
indicate the position of putative multimers. 
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virions, a decision was made to pursue experiments using only the chimaeric proteins 
that did not have a GCN4 domain (namely 5xM2e-HAstalk and 5xM2e-HAtrans).  
For both 5xM2e-HAstalk and 5xM2e-HAtrans proteins, corresponding bands could be 
observed throughout days 3, 5 and 7; day 3 seemed to have the highest expression 
profiles (Figure 6). Moreover, changing the OD600 of recombinant Agrobacterium 
(0.25/0.5/1.0) did not have a significant effect on expression levels for both proteins 
Figure 6 | Time trial of 5xM2e-HAstalk and 5xM2e-HAtrans expression in Nicotiana benthamiana using 
different expression vectors (pRIC 3.0 and pEAQ-HT). Western blots were performed to compare 
expression levels. A) 5xM2e-HAstalk in pRIC 3.0 and pEAQ-HT. B) 5xM2e-HAtrans in pRIC 3.0 and pEAQ-
HT. Infiltration was performed at OD600 0.5 and proteins were detected using the monoclonal M2 
antibody 14C2. –ve pRIC/pEAQ-HT – empty expression vectors; dpi – days post infiltration; M – molecular 
marker.  Black arrow indicates the position of the respective protein (~ 20 kDa), red arrows indicate the 
position of putative multimers. 
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(data not shown). Therefore, all further infiltrations were performed using recombinant 
Agrobacterium at an OD600 of 0.5.  
Direct comparison of expression levels between different vectors using densitometry on 
western blots showed that highest expression of 5xM2e-HAstalk was obtained using the 
pEAQ-HT vector, followed by pRIC 3.0 (Figure 6A). However, for 5xM2e-HAtrans, pRIC 
3.0 seemed to result in higher expression levels than pEAQ-HT (Figure 6B). These results 
were also confirmed by indirect ELISA using the anti-M2 commercial antibody 14C2 
(data not shown). Also, it is worth mentioning that it was not possible to detect bands 
corresponding to recombinant proteins on Coomassie stained SDS-PAGE gels (data not 
shown).  
Infiltrated leaves were examined for the visible effects caused by using different 
expression vectors. Plants infiltrated with infiltration medium only, served as a control 
for evaluating the effects caused by infiltration with the different recombinant 
Figure 8| Photographs of leaves infiltrated with 5xM2e-HAtrans in three different expression vectors: 
pTRAc-HT, pEAQ-HT and pRIC 3.0. Leaves were infiltrated at an OD600 of 0.5 and photographed 3 days 
post infiltration. Plants infiltrated with infiltration medium served as a negative control. 
Figure 7| Changes in the primary sequence of GCN4 define its oligomerization. The dimerizing 
sequence corresponds to wild-type GCN4; tetramerizing sequence was obtained from the study by 
Harbury et al., 1993.  
72 
 
constructs. Leaves infiltrated with the pTRAc-HT or pEAQ-HT set of constructs developed 
slight signs of chlorosis at 3 dpi (Figure 8), with leaves progressively becoming more 
chlorotic over the last days of the time-trial (7 dpi), showing initial signs of necrosis at 
the injection sites (data not shown). On the other hand, leaves infiltrated with the pRIC 
3.0 set of constructs showed severe signs of chlorosis at 3 dpi (Figure 8); these symptoms 
worsened progressively over the course of the time-trial, resulting in severely necrotic 
leaves at 7 dpi (data not shown). 
3.3.4. Small-scale optimization of native M1 protein expression in N. benthamiana 
Following optimization of fusion protein expression, I proceeded with expression of the 
native influenza matrix protein 1 (M1). M1 has been shown to promote VLP formation 
in other studies, hence I decided to evaluate its effect when co-expressed with the fusion 
proteins. 
As previously, initial expression trials with M1 involved the harvesting of leaf discs 
several days post infiltration (day 1, 3, 5 and 7) followed by PBS extraction and TSP 
determination. M1 expression levels were further compared between the three 
expression vectors pTRAc-HT, pRIC 3.0 and pEAQ-HT.  
Figure 9 | Western blot of M1 expression in Nicotiana benthamiana using different Agrobacterium 
densities and expression vectors (pTRAc-HT; pEAQ-HT; pRIC 3.0). Infiltration was performed at           
OD600 0.5 and proteins were harvested at 3 dpi and detected using the monoclonal anti-M1 antibody.                    
M – Molecular marker. Black arrows indicate the position of the M1 protein. 
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M1 protein expression in plants was readily detected at 3 dpi using all three expression 
vectors, as shown in Figure 9. As expected, a band of approximately 26 kDa was 
observed for both pRIC 3.0 and pEAQ-HT, whereas a slightly higher band was obtained 
using the pTRAc-HT due to the presence of a histidine tag. Overall, pRIC 3.0 seemed to 
give higher expression levels than the pTRAc-HT and pEAQ-HT vectors, as determined 
by densitometry (Figure 8). Increasing the optical densities of recombinant 
Agrobacterium had little effect on protein expression, but it did increase necrotic 
symptoms of infiltrated leaves (data not shown). Hence, I proceeded with an OD600 of 
0.5 for large-scale infiltrations to be in conformity with the 5xM2e fusion proteins.              
Figure 10| Analysis of fusion protein co-expression with the M1 core protein. Crude extracts were 
harvested at 3 dpi. A) Western blot of fusion proteins co-expressed with M1; fusion proteins were 
detected using the anti-M2 14C2 monoclonal antibody. B) Western blot of M1 co-expression; M1 was 
detected using the anti-M1 rabbit serum. C) Indirect ELISA of fusion proteins single and co-expressed 
with M1. The markers indicate the mean value of triplicate samples and error bars indicate the standard 
error of the mean (**p<0.001; *** p<0.0001).  -ve – Empty pRIC vector; E. coli – M1 expressed in E. coli. 
M – Molecular Marker; Single – Single expression; Co – Co-expression.  
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It is worth noting that the plant M1 could also be detected with the rabbit serum 
produced in Chapter 2 (See chapter 2.3.3). 
3.3.5. Co-expression of M1 with 5xM2e-HAstalk and 5xM2e-HAtrans  
Once the optimal expression conditions for each protein were determined, it was 
possible to proceed with co-expression trials. Co-expression was performed by 
infiltrating plants with a mixture of recombinant agrobacteria containing pRIC-M1 and 
either pEAQ-5xM2e-HAstalk or pRIC-5xM2e-HAtrans; at a ratio of 1:1. All recombinant 
agrobacteria were used at a final OD600nm of 0.5 and leaf material was harvested at 3 dpi. 
Western blot analysis of crude extracts confirmed the presence of both M1 (Figure 10B) 
and fusion proteins (Figure 10A); indicating that the proteins could be expressed 
together. However, for both fusion proteins and M1, co-expression resulted in fainter 
bands than expression alone (Figure 10). This was also observed when different 
expression vectors were used (data not shown). To confirm these results, crude extracts 
from plants either single or co-infiltrated with M1, were used to coat ELISA plates. Fusion 
proteins were then detected using the 14C2 monoclonal antibody and absorbances 
were compared between samples (Figure 10C). As shown in figure 10C, co-infiltrating 
5xM2e-HAstalk and 5xM2e-HAtrans with the M1 protein resulted in significantly lower 
absorbance values compared to when both fusion proteins were expressed on their 
own. Also, between the two singly expressed chimaeric proteins, the absorbance 
corresponding to 5xM2e-HAtrans showed a 4-fold increase in signal compared to the 
5xM2e-HAstalk protein (Figure 10C).  
3.4. Discussion 
Recent developments in the field of transient expression in plants have made plant-
based manufacturing of influenza vaccines in particular, a promising alternative to more 
classical approaches based on egg- or cell-based systems (Thuenemann et al. 2013; 
Lomonossoff 2016). Several groups have been successful at the production of influenza 
structural proteins in plant expression systems, specifically whole-plant N. benthamiana 
(D’Aoust et al. 2008; Mardanova et al. 2015; Mortimer et al. 2012).   
In this study, I focused on using N. benthamiana plants to rapidly and efficiently produce 
a new candidate vaccine for influenza A. For this, I designed and engineered several 
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chimaeric proteins with potential to present the M2e peptide in a membrane-anchored 
form on the surface of VLPs. Although the M2e peptide is relatively well conserved 
amongst different influenza strains, there are few amino acid changes between 
positions 10 - 23, depending on the host species where the virus was isolated from (Liu 
et al. 2005). Therefore, 33 M2e peptide sequences from different influenza A strains 
were aligned to create a new M2e consensus sequence. This consensus sequence was 
used on its own (1xM2e) or in fusion with four other M2e sequences from human, swine, 
and avian origin (5xM2e) to further enhance the breadth of cross-protection. In total, 
two avian, one human, one swine and the consensus M2e sequences were fused in 
tandem to create 5xM2e.  
To enhance the immunogenicity of M2e sequences, several carriers have been 
previously used, such as the TLR5 ligand flagellin (Huleatt et al. 2008; Mardanova et al. 
2015), hepatitis B virus core (HBc) particles (De Filette et al. 2005), or even recombinant 
adenoviruses (Price et al. 2010). However, here I used the HA glycoprotein as a scaffold 
to present the five M2e tandem repeats (5xM2e) on the surface of VLPs. Previously, 
D’Aoust et al. (2008) demonstrated that when expressed in N. benthamiana, the full-
length HA protein formed highly immunogenic membrane-derived particles resembling 
the shape of native influenza virions. Hence, I investigated if similar particles could be 
obtained in N. benthamina, by replacing the immune-dominant globular head of the HA 
with the 5xM2e repeats. These M2e-HA VLPs, contrary to the case with other carriers, 
would present the M2e peptides in a highly immunogenic, membrane-anchored form, 
thus hopefully mimicking their native conformation. VLPs that resemble the native 
structure of the virus have been shown to induce CD4 T-cell proliferation and cytotoxic 
T-cell immune responses in vitro, and to stimulate CD8 T-cells via dendritic cell-mediated 
antigen cross-presentation (Song et al. 2010; Kang et al. 2012).  
To maximize the chances of obtaining immunogenic VLPs, the 5xM2e peptide was fused 
to either the stalk domain or the transmembrane domain of the HA protein. 
Furthermore, the tetramerizing leucine zipper domain GCN4 was included in some of 
the chimaeras to possibly increase their immunogenicity as suggested by De Filette et 
al. 2008.  
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Six different chimaeric proteins were designed in total: 5xM2e-GCN4-HAstalk, 5xM2e-
GCN4-HAtrans, 5xM2e-HAstalk, 5xM2e-HAtrans, 1xM2e-HAstalk and 1xM2e-HAtrans.  
Because the 5xM2e-GCN4-HAstalk construct contained all necessary domains to create 
the remaining chimaeras, several compatible restrictions enzyme sites were introduced 
at strategic locations on the 5xM2e-GCN4-HAstalk sequence (Figure 1). This allowed me, 
through specific enzyme digestions, to rapidly clone all five other chimaeras from the 
5xM2e-GCN4-HAstalk sequence.  
Small-scale expression trials of the different M2e-HA fusion proteins in plants were first 
performed using the pTRAc-HT vector. Previously in our group, Mortimer et al. (2012) 
showed successful expression of both full-length and truncated HA proteins in plants 
using the non-replicating pTRAc vector system based on the cauliflower mosaic virus 35S 
promoter (Maclean et al., 2007). However, despite having used different expression 
conditions, the pTRAc-HT vector only showed detectable expression levels for one of the 
six M2e-HA fusion proteins (namely 5xM2e-HAstalk). These results were consistent 
either when the 14C2 antibody or an anti-histidine antibody was used, suggesting that 
the lack of expression observed was probably due to the vector used and not the 
detection method. Hence, I proceeded with expression trials using the two remaining 
vectors pEAQ-HT and pRIC 3.0. 
Expression using the pEAQ-HT and pRIC 3.0 vectors resulted in detectable protein levels 
after only 3 dpi, for 4 out of 6 fusion proteins: 5xM2e-GCN4-HAstalk, 5xM2e-GCN4-
HAtrans, 5xM2e-HAtrans and 5xM2e-HAstalk. Differences in the sequences between 
pTRAc-HT and pEAQ-HT or pRIC 3.0 could be attributed to the expression profiles 
observed. For instance, the pEAQ-HT vector includes the silencing suppressor gene p19 
on the same T-DNA, which ensures that both the gene of interest and the silencing 
suppressor are transferred to the same plant host cells (Sainsbury et al. 2009). 
Alternatively, pRIC 3.0 possesses the Bean yellow dwarf virus replication-associated 
elements between the left and right borders for T-DNA integration that allows for the 
vector to self-replicate inside the plant cells resulting in increased protein expression 
(Regnard et al. 2010). Although using different approaches to enhance recombinant 
protein expression, both pEAQ-HT and pRIC 3.0 showed higher protein levels than 
pTRAc-HT (Figure 4, 5 and 6), which is in conformity with previous studies (van Zyl et al. 
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2016; Regnard et al. 2010). Therefore, the pEAQ-HT and pRIC 3.0 vectors were used for 
all further plant expression work.  
As previously mentioned, only four out of the six M2e-HA fusion proteins could be 
detected on western blots. The two remaining proteins, 1xM2e-HAstalk and 1xM2e-
HAtrans could never be detected despite several attempts (Figure 5B). Given the high 
expression profiles observed for the 5xM2e fusion proteins using pRIC 3.0 and pEAQ-HT, 
it is highly probable that the 1xM2e-HAstalk and 1xM2e-HAtrans protein were being 
expressed but could not be detected by the anti-M2 monoclonal antibody (14C2) 
because they only possessed the consensus M2e peptide. These results are in 
agreement with previous studies that suggested that repeated M2e tandem copies were 
more reactive to specific antibodies than wild-type M2 proteins.                                   
However, because 1xM2e-HAstalk and 1xM2e-HAtrans could never be detected, it was 
not possible to measure the difference in reactivity between the 1x and 5xM2e 
constructs. Detection using more broad antibodies, such as a polyclonal anti-M2 
antibody, should therefore be investigated.  
Interestingly, when detected on western blots, all four 5xM2e proteins ran at higher 
molecular weights than what was predicted in silico (Table 3). Analysis of the 5xM2e-HA 
sequences using the NetNGlyc 1.0 program predicted three N-glycosylation sites for 
5xM2e-GCN4-HAstalk / 5xM2e-HAstalk; and two for 5xM2e-GCN4-HAtrans / 5xM2e-
HAtrans, which would have contributed to the respective 10 kDa and 7.5 kDa increased 
molecular weight bands. These results are in agreement with previous reports which 
showed that full-length recombinant HA expressed in Nicotiana benthamiana, is 
glycosylated, and thus runs at higher molecular weights (Kanagarajan et al. 2012; 
Kalthoff et al. 2010). To confirm the predicted glycosylation, future work should focus 
on enzymatic de-glycosylation cleavage of recombinant proteins and subsequent 
western blot visualization of smaller bands.  
In addition to the increase in molecular weight, several extra bands corresponding 
approximately to multiples of the size of the original band could be detected in 
denaturing SDS-PAGE gels. In agreement with previous observations that recombinant 
HA forms oligomers upon heterologous expression (D’Aoust et al. 2008; Weldon et al. 
2010), I hypothesize that these bands correspond to dimer, trimer and possibly tetramer 
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formations of the respective M2e-HA proteins. This would suggest that denaturation by 
SDS was incomplete, which possibly corroborates previous reports that HA-based 
influenza particles are thermally stable under neutral pH (Kissmann et al. 2011).  
It is important to note that, practically only the dimer band could be observed for the 
constructs containing the GCN4 domain, whereas for the proteins lacking the GCN4 
domain, all three conformations (dimers, trimers and tetramers) were clearly visible 
(Figure 5 and 6). These results were surprising since the GCN4 domain used in this study 
was supposed to promote tetramer formation and not dimers.                                        
However, Harbury et al. (1993) reported that small changes in buried hydrophobic 
amino acid residues of the GCN4 sequence, are key factors in determining whether the 
GCN4 would form dimers, trimers or tetramers (Harbury et al., 1993). An alignment of 
these GCN4 sequences compared to the one used in this study revealed eight amino 
acid changes which promoted dimerization instead of tetramerization (Figure 7). 
Therefore, since neither the HA nor the M2 proteins form dimers in native virions, and 
that epitope conformation has been shown to be a crucial factor in the efficacy of anti-
viral immune responses (Brunel et al. 2006; Blokhina et al. 2013; Staneková & Varečková 
2010; Weldon et al. 2010); I decided to only focus on characterization of the two M2e-
HA fusions lacking the GCN4 domain. 
Expression profiles of 5xM2e-HAstalk and 5xM2e-HAtrans fusion proteins were 
compared by western blotting (Figure 5 and 6). Using the pEAQ-HT vector, both proteins 
could be detected at similar levels from days 3 to 7, whereas, when the pRIC 3.0 vector 
was used, protein expression peaked at 3 dpi and then gradually decreased over the 
following days, finally being undetectable at 7 dpi. These results seemed to coincide with 
the physical appearance of leaves, where, leaves infiltrated with pEAQ constructs 
showed little necrosis up to day 7, while leaves infiltrated with pRIC constructs already 
showed necrotic symptoms after day 3 (Figure 8). This difference in protein 
accumulation over time could be attributed to the presence of the p19 silencing 
suppressor in the pEAQ-HT sequence and not on pRIC 3.0.  
Post-transcriptional gene silencing (PTGS) is a general plant response that can limit the 
efficiency of Agrobacterium-mediated transient expression (Voinnet et al. 2003). 
Numerous studies have shown that PTGS can be suppressed by co-expressing viral 
79 
 
silencing suppressors such as the p19 from the tomato bushy stunt virus.                    
Another explanation could be that the self-replicating properties of the pRIC 3.0 vector, 
which lead to increased transgene copy number, end up exhausting the leaves resources 
after short periods of time, causing them to eventually die. If this is the case, it should 
follow that longer genes will have a more detrimental effect on infiltrated leaves than 
shorter ones. Hence, the difference in size of 582 bp between the 5xM2e-HAstalk and 
5xM2e-HAtrans sequences could explain why plants infiltrated with pRIC-5xM2e-
HAstalk showed decreased protein accumulation compared to pRIC-5xM2e-HAtrans. 
These results demonstrate the importance of testing several different expression 
vectors when expressing new constructs for the first time. 
Once the best expression conditions for the two M2e-HA chimaeric proteins were 
determined, it was possible to investigate the effects of M1 co-expression. The matrix 
protein 1 (M1) is the most abundant influenza A protein, and forms the inside coat of 
the native influenza virion (Howley 2013). Lying just beneath the lipid envelope, M1 is 
able to interact with both the transmembrane domain of the glycoprotein spikes and 
the internal ribonucleoprotein particles, thus forming a bridge that allows other 
structural proteins to assemble and form a complete virion structure (Ali et al. 2000; 
Ruigrok et al. 2000). Most of the influenza-VLP production studies, including the Kim, 
Lee, et al. (2013) study on which I based the fusion protein design, consider that M1 is 
an imperative factor for correct VLP formation (Song et al. 2011; Tang et al. 2011; 
Thompson et al. 2015). Hence, I decided to evaluate its effect when co-expressed with 
the fusion proteins.  
To obtain the highest expression conditions for co-expression, I first had to optimize M1 
single expression. Although there is an extensive number of studies mentioning the 
successful expression of recombinant M1, D’Aoust et al. (2008)  have been the only ones 
that showed it using a plant production system (D’Aoust et al. 2008). Here, when run on 
western blots, our plant-expressed M1 produced a band of approximately 26 kDa which 
corresponds approximately to the size of M1 from native virus (Theresa Latham & 
Galarza 2001). As expected, this band could be detected with either our anti-M1 rabbit 
serum or a commercial monoclonal anti-M1 antibody. I have shown that amongst the 
conditions tested, best accumulation of the M1 protein was found 3 days after 
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infiltrating leaves with pRIC-M1 at an OD600 of 0,5. Further increasing the cell density of 
the recombinant constructs to an OD600 of 1.0 did not have any effect on M1 expression; 
it did however cause necrosis of the plant leaves. Agrobacterium has been well 
characterized to cause necrosis in many plant species (Wroblewski et al. 2005), hence, 
it is possible that by increasing their concentration, A. tumefaciens cells may have played 
a detrimental part in normal plant regulatory functions. Therefore, by infiltrating with 
an OD of 0.5, I was able to find an equilibrium between protein expression and the 
necrotic effect of Agrobacterium. 
In their study, D’Aoust et al. (2008) showed that the co-expression of HA and M1 in 
plants led to a substantial decrease in HA levels. Here, co-expressing the 5xM2e-HAstalk 
and 5xM2e-HAtrans fusions with M1 also resulted in a significant decrease in fusion 
protein accumulation, as shown by western blot and ELISA experiments.                          
These findings are contradictory with previous studies in both insect and mammalian 
cells, where, co-expression of M1 and HA proteins increased VLP production, rather than 
HA expressed alone (Tang et al. 2011; Choi et al. 2013). Although the causes for these 
discrepancies remain unknown, it is possible that the production of M1-derived 
influenza VLPs is affected by the expression system used. 
3.5. Conclusions 
In summary, in this work I designed six M2e-HA fusion proteins with potential to form 
VLPs. From these six, I selected the most promising two proteins based on expression 
levels and sequence analysis; namely, 5xM2e-HAstalk and 5xM2e-HAtrans. These two 
proteins were readily expressed in N. benthamiana plants after only 3 days post 
infiltration. Although optimizations increased the accumulation of fusion proteins, 
expression levels were still low since recombinant proteins were never detectable on 
Coomassie-stained SDS-PAGE gels. This is similar to recombinant expression levels seen 
for plant-produced HIV p17 ⁄ p24 (Meyers et al. 2008). Further improvements in 
recombinant expression may be achievable by optimizing several parameters such as 
the G+C content of the coding genes, the extraction buffer used, the temperature of 
incubation after infiltration and also targeting the recombinant proteins to different 
cellular compartments, namely the apoplast (Jung et al. 2015; Maclean et al. 2007; 
Mortimer et al. 2012; D’Aoust et al. 2008).  
81 
 
Furthermore, despite observing a substantial drop in fusion protein accumulation levels 
after co-expression with M1, these proteins were still detectable on western blots. 
Hence, in views of the many contradictory conclusions regarding co-expression with the 
M1 protein, I decided to investigate the formation of M2e-HA VLPs with and without 
M1. 
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Chapter 4: Characterization and purification of M2e fusion 
VLPs 
4.1. Introduction 
Virus-like particles (VLPs) have recently emerged as a promising vaccine platform for 
influenza due to their non-infectious nature and effective presentation of antigens (Shoji 
et al. 2015; Kang et al. 2012). Because influenza viruses are constantly undergoing 
antigenic changes (antigenic drift and shift), the ease/speed of VLP production is another 
advantage over current live vaccines (Jain et al. 2015). Several different influenza 
vaccine candidates based on VLP technology, are under investigation and have shown 
promise in preclinical and clinical trials (Landry et al. 2010; Herzog et al. 2009; López-
Macías et al. 2011; D’Aoust et al. 2010; Choi et al. 2013). Most of these VLP vaccines 
have been designed to fight against specific influenza strains because they were 
formulated using the full-length haemagglutinin (HA) and/or neuraminidase (NA) 
structural proteins as main antigens.  
However, VLPs presenting more conserved antigens (such as the M2e or the HA stalk 
domain) capable of eliciting broader immune responses, have also been described 
(Ibañez et al. 2013; Kim, Lee, et al. 2013; Steel et al. 2010). To present these conserved 
antigens on the surface of VLPs, chimaeric VLPs can be engineered, where the target 
conserved epitopes are genetically incorporated within the primary sequence of the VLP 
structural subunits. If successfully incorporated into VLPs, the target epitope will be 
displayed in the same conformation and density as the structural subunit it was fused 
to (Bárcena & Blanco 2013).  
Nevertheless, generating chimaeric VLPs is still largely empirical. Current computational 
models of VLP formation can give an indication on how to design the chimaeric proteins, 
but it still is almost impossible to predict whether specific peptides will self-assemble 
into VLPs (Bárcena & Blanco 2013). The only method to confirm successful VLP assembly 
is by undergoing VLP characterization in vitro (Zeltins 2013).   
Transmission electron microscopy (TEM) is the most used technique to assess VLP 
formation (Williams & Carter 2009); however, the use of purified samples is 
recommended for TEM visualization, because crude extracts contain large amounts of 
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unwanted proteins and other debris that can mask or interfere with VLP detection. 
Density gradient ultracentrifugation has been extensively used for the purification of 
both live viruses and VLPs (Zeltins 2013). Although in industrial-scale processes, the use 
of ultracentrifugation has some restrictions due to increased labor intensity and lack of 
scalability; at the laboratory level, ultracentrifugation is more than adequate for 
screening new constructs which are expected to lead to the formation of VLPs (Vicente 
et al. 2011).   
In this section of the study, I investigated if the two plant-produced fusion proteins 
5xM2e-HAstalk and 5xM2e-HAtrans, would successfully self-assemble into VLPs. 
Furthermore, I compared if these VLPs could be assembled solely using the M2e-HA 
fusions, as with the full-length HA protein, or if they required co-expression with M1. 
VLP characterization was performed by analyzing purified samples using transmission 
electron microscopy.  
4.2. Materials and methods 
4.2.1. Large scale infiltration 
The proteins and respective expression vectors that were used for large scale infiltration 
were: pRIC-5xM2e-HAtrans, pEAQ-5xM2e-HAstalk and pRIC-M1. Furthermore, the       
wild-type HA protein (in the pEAQ-HT vector, (A/Viet Nam/1194/2004 H5N1)) was also 
used as a positive control for VLP formation and the empty pRIC vector was used as a 
negative control. An overview of the general procedure used in this sections is illustrated 
in Figure 1.  
For vacuum infiltration, recombinant Agrobacterium tumefaciens was grown as 
described previously (Section 3.2.2) in LBB enriched medium (0.25 % tryptone, 1.25 % 
yeast extract, 0.5 % NaCl, 10 mM 2 L (NLMorpholino) ethanesulfonic acid (MES) pH 5.6), 
induced overnight with 20 µM acetosyringone and diluted to an OD600 of 0.5 in 
infiltration medium. 
Large scale vacuum infiltration was performed as described by Marillonnet et al. (2005). 
Briefly, whole plants were submerged in 1 L of bacterial suspension, and placed in a 
vacuum chamber. Then, a vacuum of -90 kilopascal (kPa) was maintained for 5 seconds, 
and rapidly released (10-15 kPa.sec-1). This process would be repeated 2 to 3 times. 
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After infiltration, the plants were grown at 22 °C under 16 hrs/8 hrs light/dark cycles 
until harvested.    
4.2.2. Crude protein extraction 
For protein extraction, whole leaves were harvested at 3 dpi and immediately weighed. 
Crude extracts were prepared in 3 v/w extraction buffer (1 x PBS composition: 137 mM 
NaCl, 1.8 mM KH2PO4, 10 mM Na2HPO4, 2.7 mM KCl, pH 7.4) using a T25 digital 
ULTRALTURRAX® homogenizer (IKA). Homogenized extracts were subsequently clarified 
by passing it through two folds of miracloth with a pore size of 22-25 µm (475855-IR, 
Millipore, Merck, Germany), followed by a centrifugation step at 15,000 x g for 10 min. 
The supernatant representing the crude leaf extract was collected for purification.  
Figure 1| Overview of the general steps that were used for M2e-HA VLP 
purification and characterization. 
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4.2.3. Apoplast extraction 
To extract the apoplastic fluid from infiltrated plants, the infiltration-centrifugation 
technique described by Lohaus et al. (2001) was used. As previously, leaves from vacuum 
infiltrated plants were harvested at 3 dpi and weighed. Intact leaves were then 
infiltrated with 1 x PBS, using the vacuum infiltration method described above, except 
that the infiltration process was only performed once per plant batch. This prevented 
the loss of recombinant proteins. 
PBS-infiltrated leaves were then carefully rolled and loaded into 50 mL syringes with the 
plungers removed. Syringes containing leaves were centrifuged twice for 20 min at       
800 x g in a Beckman-Coulter centrifuge using a JA-14 rotor to extract crude apoplastic 
extract.   
4.2.4. Iodixanol cushion pelleting 
Iodixanol cushion ultracentrifugation was based on purification of influenza particles by 
Yang et al. (2009). After extraction, either crude or apoplastic extracts were overlaid 
onto 4 ml of 14 % iodixanol solution (Optiprep® Sigma-Aldrich, Germany) prepared in 
38.5 mL Ultra-Clear™ centrifugation tubes (Beckman Coulter) using 1 x PBS. Sometimes, 
the apoplastic extraction volume was too low to completely fill the ultracentrifugation 
tubes; in these cases, 1 x PBS was simply added to fill tubes. Samples were 
ultracentrifuged for 90 min at 27,000 rpm (89,527 x g) at 4 oC in a SW 32 Ti rotor 
(Beckman). Pellets were re-suspended in 750 - 1000 µL 1 x PBS and kept at 4 oC for 
Western blot/TEM analysis and purification. 
4.2.5. Density gradient purification 
The pellets from crude extracts were further purified by density gradient purification. 
Briefly, re-suspended pellets were loaded on top of a 10 – 50 % iodixanol gradient       
(with 10 % increases) in a 5 mL Ultra-Clear™ centrifugation tubes (Beckman Coulter). 
The discontinous gradient was ultracentrifuged at 32,900 rpm (102,621 x g) for 2 hrs at 
4oC in a SW 55 Ti rotor (Beckman Coulter). After centrifugation, 0.5 mL fractions were 
collected from the bottom of the tube using a Foxy® Jr. Fraction Collector (Teledyne Isco, 
NE, United States of America). Collected fractions were analyzed by western blotting 
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and TEM. Density of iodixanol-containing solutions was measured using the Digital      
PAL-3 Pocket refractometer machine (Atago®, Japan). 
4.2.6. Coomassie-stained SDS-PAGE gels and western blots 
Samples from every purification step were analyzed by Coomassie-stained gels and 
western blots as described in section 3.2.2. For western blots, proteins were detected 
with either 1:5000 anti-M2 14C2 monoclonal IgG antibody (Abcam, UK), 1:5000 anti-M1 
GA2B monoclonal IgG antibody (Abcam, UK), 1/5000 anti-H5 (H5N1) monoclonal IgG 
antibody [8D2] (Abcam, UK) or 1/10000 serum from rabbits immunized against M1 
(Chapter 2). Antibodies produced in mice were detected with 1/10000 anti-mouse IgG 
(whole molecule) alkaline phosphatase conjugated antibody produced in goat (Sigma-
Aldrich, Merck, Germany), whereas the rabbit serum was detected with 1/10000 anti-
rabbit IgG (whole molecule) alkaline phosphatase conjugated antibody, also produced 
in goat (Sigma-Aldrich, Merck, Germany). Band densitometry analysis was performed 
using the ImageJ open-source software (ImageJ developers). 
4.2.7. Transmission electron microscopy 
TEM was carried on both crude and purified samples to analyze VLP formation. Before 
applying samples, copper grids were made hydrophilic by glow discharging at 25 mA for 
30 s using a Model 900 SmartSet Cold Stage Controller (Electron Microscopy Sciences, 
United States of America). Glow-discharged grids were then placed on samples for 5 min 
and washed five times with distilled sterile water. Thereafter, samples were negatively 
stained on uranyl acetate for 30 s and again for 5 s and viewed using a Tecnai™ F20 
Scanning Transmission Electron Microscope (FEI, OR, United States of America).   
4.2.8. Immuno-gold labelling of VLPs 
For immuno-gold labelling, glow-discharged grids were placed on samples for 30 min at 
room temperature, followed by six washes with sterile water. Thereafter, coated grids 
were incubated for 1 hr with either the 14C2 mouse anti-M2 antibody (Abcam, UK) or 
the 8D2 mouse anti-H5 (H5N1) antibody (Abcam, UK), both diluted to 1:100 in 20 mM    
1 x TBS. After washing grids four times with sterile water, the anti-mouse gold 
conjugated IgG (10 nm gold particles) (Abcam, UK) was added at a 1/100 dilution in         
20 mM 1 x TBS and left to incubate for another 15 min at room temperature. Finally, the 
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grids were washed four times and negatively stained as previously, before visualization 
using a Tecnai™ F20 Scanning Transmission Electron Microscope (FEI, OR, United States 
of America).   
4.3. Results 
4.3.1. Vacuum infiltration and purification 
Using the expression conditions optimized previously, whole plants were vacuum 
infiltrated with recombinant Agrobacterium. Plants were either infiltrated with the 
fusion proteins alone or with the M1 protein. A positive control for VLP formation was 
also included by infiltrating plants with the full-length HA protein                                         
(A/Viet Nam/1194/2004 H5N1).  
Following large-scale vacuum infiltration, whole leaves were harvested and 
homogenized using a mechanical blender. The homogenate was then centrifuged,       
and the supernatant collected and filtered through Miracloth to remove large 
particulates. The supernatant was then loaded onto a 14 % iodixanol cushion and       
ultra-centrifuged to pellet any particles that could be in the sample. This allowed me to 
concentrate the samples, thus reducing the working volume for the gradient step.      
Figure 2| Iodixanol cushion step after ultracentrifugation showing the formation of a band and a 
pellet. 
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After centrifuging, a translucent band could be observed above the iodixanol cushion 
(Figure 2). This was observed for all samples, including plants infiltrated with an empty 
vector (negative control). An aliquot of the supernatant as well as the band was collected 
and the pellet re-suspended in PBS for western blot analysis (Figure 3). Immunoblot 
analysis revealed that both 5xM2e-HAstalk (Figure 3A) and 5xM2e-HAtrans                     
(data not shown) fusion proteins, as well as, the recombinant HA (Figure 3B) 
accumulated mostly in the pellet, but were also present between the sample and 
iodixanol cushion (band). The supernatant also contained trace amounts of recombinant 
protein. Co-expression with M1 gave similar results (data not shown). 
Since recombinant proteins were detected throughout the whole tube, I proceeded with 
analyzing the aliquots collected from the supernatant, the band and the pellet using TEM 
(Figure 4). Despite the background signal, TEM analysis of infiltrated leaf tissue 
expressing 5xM2e-HAstalk + M1 showed putative particles of around 80 - 120 nm 
diameter, in both the crude and pellet samples (Figure 4, red arrows). On the other hand, 
the extracts from the band fractions presented several structures of different shapes 
but nothing consistent with VLPs could be found. The supernatant samples where 
almost completely devoid of any particular structures. Similar results were observed for 
the remaining constructs (5xM2e-HAstalk/ 5xM2e-HAtrans/ 5xM2e-HAtrans + M1)   
(data not shown) and for the positive HA control (Figure 4). No particles were observed 
on extracts from leafs infiltrated with an empty pRIC 3.0 vector (negative control)        
(data not shown).  
Figure 3| Western blots analysis of aliquots collected during the iodixanol cushion step.  A) Analysis of 
5xM2e-HAstalk after partial purification. Proteins were detected using the monoclonal anti-M2 
antibody. B) Analysis of the full-length HA protein after partial purification. Detection was performed 
using the monoclonal anti-HA antibody. M – Molecular Marker; Sup – Supernatant fraction; Band – Band 
fraction; Pel – Pellet fraction; Cd – Crude extracts. 
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Based on these results, the iodixanol cushion pellets fractions were further analyzed 
using a iodixanol density gradient ultracentrifugation consisting of 10 – 50 % iodixanol 
(in 10 % increments). This extra step served to concentrate the putative VLPs, while 
removing some of the background signal.  
Following ultracentrifugation, fractions were collected from the density gradient and 
monitored for recombinant protein abundance using dot blots detected with anti-M2, 
anti-HA or anti-M1 antibodies and serum. Densitometry was used on dot blots to 
compare protein levels between different fractions. Densitometry analysis confirmed 
that all chimaeric proteins as well as M1 and HA, mostly accumulated between            
fractions 5 - 7(Figure 5A, C and E). These fractions represented an iodixanol density 
gradient ranging from 32 – 19 % iodixanol, as determined using the refractometer 
machine.  
To confirm that the intensity peaks corresponded to the presence of desired 
recombinant proteins, western blots were performed for each fraction (Figure 5B, D and 
F). Detecting fractions containing the M2e fusions using an anti-M2 monoclonal 
antibody resulted in clear corresponding bands (± 53 kDa for 5xM2e-HAstalk/ ± 30 kDa 
for 5xM2e-HAtrans) between fractions 5 - 7. Faint bands could also be observed in 
Figure 4|Transmission electron micrographs of partially purified extracts from leafs co-expressing 
5xM2e-HAstalk + M1 or the HA protein alone. Aliquots from crude extracts or from the supernatant, 
band and pellet fractions following ultracentrifugation, were used to coat copper grids for VLP detection. 
Scale bars are 100 nm. Red arrows indicate putative VLPs. 
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fractions 4 and 8; but no bands were observed in fractions 1 - 3 and 9. This was observed 
for single (data not shown) and co-expressed samples (Figure 5B and D). Furthermore, 
when the anti-M1 serum was used on western blots of co-expressed samples, bands 
corresponding to M1 (± 26 kDa) were also clearly visible between fractions 5 - 7; 
however, there were also fainter bands on fractions 8 and 9 (Figure 5B and D).       
Figure 5| Analysis of the iodixanol gradient purification step. The iodixanol density () was compared 
with the relative intensity of recombinant proteins () from leaf tissue co-expressing (A) – 5xM2e-
HAstalk + M1; (C) –  5xM2e-HAtrans + M1; or (E) – full-length HA, as determined by dot-blot using the 
anti-M2 antibody or the anti-HA antibody. The relative intensity of proteins from the negative control 
(empty pRIC) () was also compared from dot blots in (A). (B), (D) and (F) show western blots of the 
fractions collected from the iodixanol gradient detect with the respective antibodies. Anti-M2 and anti-
HA antibodies were used at a 1/5000 dilution; whereas the anti-M1 rabbit serum was used at a 1/10000 
dilution. 
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Western blot analysis of the HA control also revealed strong bands around fractions           
5 - 7, with some weaker bands in fractions 4 and 8 (Figure 5F). No bands corresponding 
to the desired recombinant proteins could be observed on SDS-gels stained with 
Coomassie  (data not shown). Since fractions 5-7 seemed to contain most of the desired 
recombinant proteins for all samples, these fractions were pooled together and used to 
coat copper grids for TEM visualization (Figure 6).  
Analysis of transmission electron micrographs of single expressed 5xM2e-HAstalk and 
5xM2e-HAtrans revealed that putative VLPs (Figure 6, red arrows) ranging from 80 – 120 
nm in size and with an oval shape, could be purified on the discontinuous gradient. These 
particles were in higher concentrations than with the samples analyzed before gradient 
purification. It was also possible to detect several particles that had not been completely 
assembled (Figure 6, black arrows). Moreover, irregular-shaped aggregates were also 
present in the samples (Figure 6, black arrows), possibly representing plant debris that 
was carried over the purification steps. Overall, there seemed to be no apparent 
difference in the shape, structure or size of particles from samples containing either 
5xM2e-HAstalk or 5xM2e-HAtrans. These particles were similar in size and shape when 
compared to the HA control (red arrows); with the exception that the HA samples had 
clearly visible spikes that protruded from the surface of the particles whereas the M2e 
particles did not. Co-expression with M1 did not alter the morphology of particles, but 
it reduced the concentration of particles observed (Figure 6, red arrows). Analysis of the 
fractions from leaf tissue expressing the empty pRIC negative control vector did not find 
anything consistent with VLPs (Figure 6).   
Previous studies have suggested that the cytoplasmic tail of the M2 protein is able to 
recruit M1 into the plasma membrane and thus promote viral assembly and budding 
(Chen et al. 2008; McCown and Pekosz 2006). Therefore, co-expression of the full-length 
M2 protein together with the fusion proteins and M1 was attempted (data not shown). 
However, despite several attempts, M2 expression could never be detected on western 
blots of crude extracts from infiltrated plants. Therefore, it was not possible to evaluate 
the effects of M2 co-expression.   
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Figure 6| Transmission electron micrographs of pooled fractions 5 to 7 following iodixanol 
gradient ultracentrifugation. Corner images represent pictures taken in other regions of the copper 
grids. Red arrows indicate putative VLPs, black arrows indicate incomplete particles and other 
debris. Scale bars are 50 nm. 
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4.3.2. Apoplast extraction 
Although some VLP-shaped particles could be observed for both 5xM2e-HAstalk and 
5xM2e-HAtrans after iodixanol density gradient purification, their concentration was 
very low and they were not always fully assembled. Previous studies in our group using 
the full-length influenza A hemagglutinin protein have shown that most HA-VLPs were 
observed in the apoplast fractions of infiltrated plants. Hence, to confirm VLP identity, 
proteins from the apoplastic fraction were extracted and concentrated by 
ultracentrifugation through an iodixanol cushion.  
Western blots of crude and apoplastic fractions were performed to confirm the 
presence of recombinant proteins (Figure 7). Bands corresponding to 5xM2e-HAstalk 
(data not shown), 5xM2e-HAtrans (Figure 7B) and HA (Figure 7A) could be observed in 
Figure 7| Western blot analysis of apoplast fractions. A) Analysis of leaves infiltrated with either HA 
alone or co-expressed with M1. Proteins were detected with a mixture of anti-HA antibody (1/5000) and 
anti-M1 antibody (1/5000). B) Analysis of leaves infiltrated with either 5xM2e-HAtrans alone or co-
expressed with M1. Proteins were detected with a mixture of anti-M2 antibody (1/5000) and anti-M1 
antibody (1/5000). C) Apoplast extraction of leaves infiltrated with only pRIC-M1. +ve – M1 expressed in 
E. coli. Proteins were detected with a monoclonal anti-M1 antibody (1/5000). M – Molecular Marker; Cd 
– crude extracts; Apo – Apoplastic fraction; Pel – pelleted apoplastic fraction; -ve – Apoplastic fraction 
of leaves infiltrated with an empty pRIC vector. Arrows indicate size of desired proteins.  
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both crude and apoplastic fractions. However, bands from the apoplast were generally 
fainter than those from the crude extracts. On the other hand, the M1 protein was only 
detected in the apoplastic fractions of co-infiltrated leaves; no bands corresponding to 
M1 could be observed in the apoplast of leaves infiltrated with M1 only                           
(Figure 7A, B and C). Pelleting of the apoplast samples after a cushion ultracentrifugation 
step, resulted in higher protein concentration as shown by the increase in band intensity 
(Figure 7).  
Once the presence of recombinant proteins was confirmed in the apoplastic fractions,    
I proceeded with visualization of the pelleted apoplastic fractions by TEM to analyze VLP 
formation. After coating with the samples, copper grids were immersed in either mouse 
anti-M2 or mouse anti-HA antibodies, followed by coating with an anti-mouse gold-
labeled antibody. This would allow for identification and confirmation of influenza VLPs.  
As described previously, HA apoplastic extracts examined under TEM showed circular 
particles of about 80 – 120 nm with regularly spaced spikes protruding from the VLPs 
(Figure 8). Most VLPs had small black dots attached on the surface, which corresponded 
to the gold beads that were covalently bound to the anti-mouse antibody.                             
Co-expressing the HA protein with M1 resulted in particles that were less distinct and in 
lower amounts than those observed for single expressed HA.  
Apoplastic fractions of leaves infiltrated with 5xM2e-HA-stalk or 5xM2e-HAtrans 
showed similar particles that were in higher number than the ones observed previously 
with density gradient purified extracts. Also, it is worth noting that, while for the density 
gradient purified samples, part of the structures observed corresponded to partially 
assembled particles, in the apoplastic fractions, particles were almost always complete, 
even after M1 co-expression (Figure 8). Immuno-gold experiments revealed that only 
single-expressed 5xM2e-HAstalk or 5xM2e-HAtrans samples displayed particles that had 
gold beads attached to them. However, these results could not always be reproduced 
and only a small proportion of the particles were gold immune-labeled, specially 
particles from 5xM2e-HAtrans expressed alone (Figure 8). It was never possible to 
visualize particles with gold beads for the co-expressed samples. Increasing the primary 
antibody concentration as well as its incubation time did not result in visible differences 
in the electron micrographs (data not shown). The negative control grids (apoplast 
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fraction of plants infiltrated with an empty pRIC vector) had few gold beads on the 
background but no particles could be observed.  
 
Figure 8| Immuno-gold labelling of VLPs in apoplastic extracts of infiltrated plants. The anti-M2 
antibody was used to detect the M2e-HA VLPs and the negative control sample, whereas, the anti-HA 
antibody was used to detect HA VLPs. Gold beads are 10nm in diameter, scale bars are 100nm.  
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4.4. Discussion 
In this section, I evaluated the ability of the 5xM2e-HAstalk and 5xM2e-HAtrans 
chimaeric proteins to self-assemble into VLPs using TEM analysis of purified samples. 
Producing enough plant material for VLP purification required the infiltration of whole 
plants as opposed to individual leaves. An alternative method using vacuum infiltration 
has been shown to be efficient at rapidly infiltrating multiple plants                                            
(Lai and Stahnke 2013). In this method, whole plants are first submerged in infiltration 
media containing the recombinant Agrobacterium. By creating a vacuum and suddenly 
releasing it, the pressure forces infiltration medium containing the Agrobacterium 
through the stomata and into the intercellular spaces, allowing for the entire plant to be 
infiltrated. This technique has been successfully used to produce influenza VLPs for 
clinical trials on a large scale (D’Aoust et al. 2010).   
Crude extracts from vacuum infiltrated plants were loaded on top of an iodixanol 
cushion to pellet and concentrate possible VLPs before further purification steps.           
Any free HA-derived or small plant proteins in the supernatant should not be captured 
in the pellet containing VLPs, thereby also serving as a partial purification step.                    
Western blots analysis of the different fractions collected confirmed that the majority 
of recombinant proteins accumulated in the pellet, including the HA positive control 
which is known to form VLPs. Previous work on purification of influenza VLPs, showed 
successful VLP pelleting after a cushion ultracentrifugation step (Young et al. 2015; Wu 
et al. 2010; Lai et al. 2011; Thompson et al. 2015). Most of these studies used sucrose 
for the preparation of the cushion. However, since the final purification step in this study 
was in an iodixanol gradient, I hypothesized that it would be less stressful for the VLPs 
to use the same density medium in the cushioning and gradient steps. 
However, because recombinant proteins were not only detected in the pellet, but also 
between the iodixanol cushion and the supernatant fractions, I analyzed all fractions by 
TEM to confirm that the VLPs were being pelleted. As expected, TEM visualization of the 
band and pellet samples revealed large structures that probably corresponded to plant 
membrane-derived debris and other large protein aggregates (Figure 3).                 
However, in both single and co-expressed M2e-HA fusion pellet fractions, it was possible 
to distinguish individual spherical particles, which were never visualized in either the 
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band or supernatant fractions. These particles ranged between 80 - 120 nm in diameter 
and despite the lack of characteristic HA spikes, were morphologically very similar to HA 
VLPs produced in plants (Figure 8; D’Aoust et al., 2008). These results provided 
preliminary evidence that both M2e-HA proteins could assemble into VLPs. 
To confirm that the particles observed were VLPs, the pellets were applied to a 
discontinuous gradient. This step works by layering different concentrations of iodixanol 
(10/20/30/40/50 %) and then collecting fractions for analysis after ultracentrifugation. 
Each concentration of iodixanol has a different density: different particles are separated 
according to their density, allowing for the removal of undesired plant debris.      
Iodixanol has been widely used for the purification of influenza VLPs (Thompson et al. 
2015; T. Latham & Galarza 2001; George & Aucoin 2015). Although being more 
expensive than conventional density solutions such as caesium chloride or sucrose, 
iodixanol offers certain distinct advantages (e.g. low viscosity, non-toxic to eukaryotic 
cells and it is suitable for direct TEM visualization) that makes it more suitable for 
screening new constructs which are expected to lead to the formation of VLPs                
(Gias et al. 2008).  
In agreement with previous studies using live influenza virus (Hutchinson & Fodor 2014; 
Arora et al. 1973; Hutchinson et al. 2014), immunoblot analysis of the fractions collected 
after gradient ultracentrifugation, showed that both 5xM2e-HAstalk and                     
5xM2e-HAtrans accumulated between fractions 5 - 7 corresponding to 33 % and 19 % 
iodixanol respectively. However, although proteins could be detected on western blots, 
it was never possible to distinguish corresponding bands amongst the background signal 
on Coomassie-stained SDS-gels (data not shown).  
The Coomassie Brilliant Blue R-250 reagent used here has been reported to be able to 
detect as few as 100 ng per band for most proteins. This would indicate that the 
concentration of influenza recombinant proteins after purification, was below                  
400 ng/mL and in terms of overall yield per gram of fresh weight leaves, this would be 
less than 5 mg/kg. In comparison, D’Aoust et al. 2008 have reported yields of 
approximately 50 mg/kg for the production of HA VLPs in plants. Therefore, further work 
on improving protein yield and purity must be performed for these plant-produced 
proteins to be commercially viable.  
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Nevertheless, since this was a preliminary study on the creation of new proteins that 
could form VLPs, the expression yields were not of major concern if sufficient amounts 
could be obtained for TEM analysis.  
TEM of pooled fractions 5 to 7 displayed a higher concentration of particles that were 
similar in morphology compared to the ones observed in the pellet. However, despite 
being cleaner than the pellet, small protein aggregates could still be observed by TEM 
after gradient purification. These contaminants could potentially be excluded by 
additional specialized chromatography steps such as size-exclusion, ion exchange, and 
affinity chromatography (Zeltins 2013).  Closer observation of the particles from     
5xM2e-HAtrans and 5xM2e-HAstalk showed no major differences in size compared to 
HA VLPs (Figure 6), suggesting that the particles observed in the M2e-HA samples could 
probably be VLPs. Furthermore, as previously, despite the lack of spike projections, 
particles from M2e-HA fusions had a similar appearance to HA VLPs. These results were 
expected since the surface spike projections have been associated with the HA globular 
head domain (Howley 2013), which is lacking from the M2e-HA fusions.                                       
It is possible that there are some M2e spikes protruding from the M2e-HA fusion but 
due to their small sizes, they could not be visualized under the settings used for the TEM.  
Surprisingly, no significant differences in VLP morphology, quantity or size were 
observed between the two M2e-HA fusion proteins: 5xM2e-HAstalk and                      
5xM2e-HAtrans. Since the only difference between these two proteins is the HA stalk 
domain present only in the 5xM2e-HAstalk construct, it can be hypothesized that the 
HA stalk domain does not have a significant structural impact in the formation of these 
VLPs, and that their formation is due mainly to the transmembrane domain. This would 
be in agreement with other studies that have used the HA transmembrane domain as a 
scaffold to mediate enhanced incorporation and display of enveloped proteins         
(Benen et al. 2014; Wang et al. 2007). 
Although increased concentrations of VLP-resembling particles were observed in 
gradient-purified samples, an important number of these particles seemed to be 
incomplete (Figure 6, black arrows). Previously, D’Aoust et al. (2008) have shown that in 
plants, HA-VLP assembly takes place at the cell membrane of infiltrated plants, with 
most VLPs accumulating in the apoplastic spaces between the plasma membrane and 
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the cell wall. Therefore, I hypothesized that, if successfully assembled, M2e-HA VLPs 
would follow the same pathway as HA-VLPs, and accumulate at higher concentrations 
in the apoplastic spaces of infiltrated plants.  
The apoplast is the extra-protoplasmic water-filled space of the plant cell: it is composed 
of secreted proteins like digestive enzymes, metabolites, ions and many other 
substances (Blinda et al. 1997). Proteins located in the apoplast can be easily extracted 
by vacuum infiltration with an extraction solution such as PBS, followed by a mild 
centrifugation step with leaves cut into strips to collect the apoplastic washing fluid 
(Witzel et al. 2011). Western blot analysis of apoplast extracts from infiltrated plants 
confirmed the presence of both M2e-HA fusions and the full-length HA when single or 
co-expressed. The lower protein yields observed from the apoplastic fractions (Figure 7) 
compared to crude samples are probably due to the relatively large volumes of 
extraction solution that had to be employed for harvesting of the apoplastic fluid. 
Nevertheless, TEM of apoplast fractions containing the M2e-HA fusions, showed a 
higher concentration of particles than previously observed for the purified crude 
extracts. The fact that no VLP-like structures could be observed on grids from leaves 
infiltrated with an empty vector adds strong evidence that these particles were M2e-HA 
VLPs. Interestingly, particles observed in the apoplastic fractions were almost always 
fully assembled, with very few that seemed incomplete. These findings provide tentative 
evidence that the M2e-HA VLPs follow the same pathway as wild-type HA VLPs by 
budding at the plasma membrane of infected cells. This could be confirmed with 
additional experiments by fixating infiltrated leaves with a cross-linking solution such as 
glutaraldehyde, and making ultra-thin sections for TEM analysis. This approach would 
allow for direct localization of the VLP budding process in plant cells                               
(D’Aoust et al. 2008).  
Immuno-gold labelling of M2e-HA particles using the monoclonal anti-M2 antibody was 
only partially successful as significant background signal was observed. Only the samples 
with the M2e-HA fusions expressed alone seemed to have VLPs that were successfully 
immune-labeled (Figure 8). However, given the strong background signal, it cannot be 
ruled out that the labeled particles observed could have been the result of non-specific 
antibody binding. Interestingly, M1 co-expressed samples never showed gold labeled 
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particles. This could be due to the low number of particles that were formed, or to the 
possibility that co-expression with M1 triggers a conformational change of the M2e-HA 
fusions that masks the M2e epitopes. To confirm these assumptions,                                
further investigation is required using different M2 antibodies.  
More interestingly, VLP-like particles were observed in higher numbers when the        
M2e-fusions were expressed on their own compared to when M1 was co-expressed. 
These results are consistent with the observations made in Chapter 3, where                       
co-expression with M1 decreased fusion protein accumulation. During natural viral 
infection, the HA protein is targeted to the plasma membrane through the secretory 
pathways, whereas M1 collects in the nucleus/cytosol region (Sato et al. 2003).                      
A number studies have demonstrated that VLPs without M1, can be successfully 
produced in different expression systems such as mammalian cells, insect cells or even 
plants (Chang et al. 2011; D’Aoust et al. 2008; Lai et al. 2011; Chen et al. 2007). However, 
for unknown reasons, this reduction in  VLP concentration after M1 co-expression has 
only been reported when plants were used as expression systems (D’Aoust et al. 2008). 
It is therefore possible that plants lack certain components that are necessary for 
efficient budding of M1-contining VLPs. Identification and co-expression of these 
components with the recombinant influenza proteins could possibly increase VLP 
formation in plants.  
Recently, the M2 protein has been found to promote the budding and release of the 
influenza virions, by interacting with the M1 protein (Wei et al. 2011; McCown & Pekosz 
2006; Wang et al. 2010; Chen et al. 2007). There is also evidence that co-expression of 
M2 protein with certain HAs helps in VLP formation in plants                                                             
(E.P. Rybicki, personal communication). Although the exact mechanisms for influenza 
budding formation remain unknown, it has been suggested that, interactions between 
structural proteins, such as M1 binding to the HA cytoplasmic tail, could prevent 
completion of viral budding until recruitment of other proteins, such as M2 (Iwatsuki-
Horimoto et al. 2006; McCown & Pekosz 2005; Rossman et al. 2010; Wang et al. 2010; 
Kerviel et al. 2016). However, because of its highly insoluble nature, the M2 protein is 
relatively difficult to produce in a heterologous expression system (Czabotar et al. 2004; 
Mitraki et al. 1991). This could explain why there are so few influenza VLP studies that 
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include M2 in their VLP formulations, despite its reported ability to promote particle 
formation.  
Here, I tried co-infiltrating both fusion proteins and M1, with the full-length M2 protein 
(data not shown). However, as anticipated from previous trials with E. coli,                            
M2 expression could never be detected in plant extracts and thus it was not possible to 
investigate its effect on particle formation. Nevertheless, co-expression with the            
full-length M2 protein is extremely promising to increase particle formation and should 
therefore be investigated. 
4.5. Conclusions 
Thus, based on these results I can conclude that, when expressed in N. benthamiana 
plants, the 5xM2e-HAstalk and the 5xM2e-HAtrans fusion proteins, can form VLP-like 
particles on their own and to a lesser extent by co-expression with M1. These particles, 
were similar in size and shape to native HA-VLPs without the characteristic surface 
spikes. Furthermore, particles seemed to bud at the plasma membrane, finally 
accumulating in the apoplast, as previously described (D’Aoust et al. 2008). Nonetheless, 
further investigations to fully characterize these particles in terms of structural 
composition as well as immunogenic properties are required to confirm their potential 
as influenza vaccines.  
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Chapter 5: General conclusions 
The aim of this project was to design and produce a new candidate influenza vaccine 
that could meet two major requirements: first, it would have to be rapidly produced 
using a system that could be easily scalable, to allow for a quick response in case of 
influenza pandemic. Second, because influenza A is constantly undergoing antigenic 
drifts/shifts, the vaccine would have to elicit broad immune responses that could 
provide protection against widely different Influenzavirus A strains. To meet these 
requirements, a transient expression system was utilized in N. benthamiana to rapidly 
produce virus-like particles (VLPs) displaying the M2e conserved ectopic region of the 
M2 viroporin protein. The plant expression platform has been shown to be favorable for 
the rapid production of highly immunogenic influenza virus HA-VLPs (D’Aoust et al. 
2008). This made it conceivable to obtain similar VLPs, by replacing the highly variable 
head domain of the HA protein with several tandem copies of the M2e peptide. If 
successfully assembled, these M2e-HA VLPs would have the potential to elicit broader 
immune responses than any HA-VLP or current available vaccine. 
Because available commercial antibodies against the influenza matrix proteins 1 (M1) 
and 2 (M2) are exceedingly expensive, both proteins were first expressed in E. coli in the 
form of insoluble inclusion bodies and subsequently injected into rabbits for antibody 
production. M1 expression in E. coli required little optimization and was shown to 
express at high yields, between 0.8 - 1.0 mg/mL. The rabbit serum raised from injecting 
E. coli-produced M1, could detect recombinant M1 produced in either bacteria or plants. 
This serum was used for subsequent immunoblot experiments in plants, thus reducing 
greatly the costs of the project.  
On the other hand, because of its high insolubility, the M2 protein could only be 
produced in low amounts and its expression had to be optimized by resorting to the use 
of Terrific broth. Using this highly enriched media, I was able to reach 0.2 - 0.3 mg/mL 
of insoluble M2, which was enough for rabbit injection. Nevertheless, because of its 
weak immunogenicity, the recombinant M2 was not able to induce detectable amounts 
of M2-specific antibodies in the serum of injected rabbits. It is possible that increasing 
the amounts and the purity of recombinant M2 as well as the number and the time 
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interval between each boost could result in improved immune responses against the    
M2 protein, as suggested by (Feng et al. 2006). Additional M2 protein produced in this 
way could potentially be used for future animal trials to compare its immunogenicity 
against the plant produced M2e-HA chimaeric proteins. 
To increase the chances of obtaining M2e-presenting VLPs, I designed six different     
M2e-HA fusion proteins based on the study by Kim, Lee, et al., 2013. After expression 
and sequence analysis, the two fusion proteins with the highest probability of forming 
immunogenic VLPs (5xM2e-HAstalk and 5xM2e-HAtrans) were selected for expression 
optimization and VLP characterization in N. benthamiana plants.  
Both 5xM2e-HAstalk and 5xM2e-HAtrans fusion proteins could be readily expressed in 
plants after only 3 dpi. However, although protein accumulation was increased with a 
variety of optimizations, I was never able to produce sufficient amounts to make 
production commercially viable. Further optimizations strategies have been considered 
to improve recombinant protein yields in plants (Jung et al. 2015; Maclean et al. 2007; 
Mortimer et al. 2012; D’Aoust et al. 2008).  
Such optimizations can be extremely time consuming and would be wasteful in the 
eventuality that the M2e-HA fusion proteins could not properly assemble into VLPs. 
Therefore, I decided to first evaluate VLP formation before trying any additional 
expression optimization.  
Although Kim et al., 2013 have previously shown that M2e fused to the transmembrane 
domain of Influenzavirus HA could form VLPs in insect cells, these VLPs were only 
obtained when the M1 protein was included. In the present study, using transmission 
electron analysis of density-gradient purified samples, I showed that when expressed 
alone, the 5xM2e-HAstalk and 5xM2e-HAtrans proteins successfully assembled into 
putative VLPs that were similar in size and shape to HA VLPs without the characteristic 
spikes. Surprisingly, comparison between 5xM2e-HAstalk and 5xM2e-HAtrans particles 
showed no visible differences in morphology, suggesting that the formation of these 
particles was due mainly to the HA transmembrane domain. As anticipated, the highest 
concentration of fully assembled M2e-HA particles was found in the apoplastic space of 
infiltrated plants. This provides evidence that the M2e-HA proteins were still localized 
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to the plasma membrane despite having replaced the HA globular head with the five 
M2e tandem copies. No conclusions could be drawn from immune-gold labeling 
experiments because of the background signal observed, thus additional optimizations 
are probably required.  
Furthermore, not only did co-expression with the M1 protein decrease the accumulation 
of 5xM2e-HAstalk and 5xM2e-HAtransin in crude extracts, but it also reduced the 
number of particles formed. These findings are contradictory to the study                                
by Kim, Lee, et al., 2013, where the formation of M2e-HA VLPs in insect cells was only 
reported when the M2e-HA fusion was co-expressed with M1.                                                  
These discrepancies could be attributed to the difference in expression systems used,   
as suggested by (Chen et al. 2007; Wang et al. 2010). The mechanisms leading to the 
synchronized buildup of the M2e-HA fusion proteins and M1 at the site of budding are 
complex, and could be very different depending on the expression system used. 
Moreover, it is possible that including other influenza structural proteins (such as M2) 
in the formulation of these particles, may help recruitment of M1 into the plasma 
membrane and promote the budding and release of influenza VLPs. Further work in 
comparing the expression of these M2e-HA fusions in different expression systems, as 
well as co-expressing with the M2 protein, would be of high interest. 
In summary, this study provided preliminary data on the ability of plants to produce 
chimaeric influenza VLPs. To the best of my knowledge, this is the first report of M2e-
HA chimeric VLP production using plants. Furthermore, these VLPs could be produced 
by expressing the M2e-HA proteins alone, which adds evidence that only the 
transmembrane and cytoplasmic domain of the HA protein are required for particle 
incorporation. This is also the first study that fused the two most promising conserved 
influenza peptides, M2e and the HA stalk domain, and showed that, when fused 
together, they could form VLPs in plants. Finally, this is the first proof that Influenzavirus 
M1 protein expressed in plants appears to be co-localized with HA or HA derivatives in 
VLPs when co-expressed. 
It would be interesting to evaluate the immunogenicity of these VLPs to see if they can 
induce broad immune responses. However, given the low amount of VLPs observed, it 
is highly probable that any immunogenicity study performed using the conditions              
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of this project, would not accurately reflect the full potential of these VLPs.                         
Therefore, to characterize the immunogenicity of the M2e-HA VLPs, future work should 
focus first on increasing the number VLPs formed. This could be achieved                                 
by several approaches, such as: i) increasing initial protein expression yields;                                                    
ii) complementing density gradient purification with other purification methods,          
such as chromatography; and iii) co-expressing fusion proteins with both M1 and M2.                                                             
This is by no means an exhaustive list and most probably, a combination of these 
approaches will have to be employed. It is to be hoped that others can use these 
suggestions to improve VLP formation and complete our team’s goal of making a 
universal influenza A vaccine. 
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Appendix A 
Table A1|Compilation of the M2e sequences used to create the consensus M2e 
Strain Subtype GenBank accession number 
(A/Georgia/M5081/2012) H1N1 CY148069.1 
(A/Georgia/M5081/2012) * CY147988.1 
(A/Brisbane/59/2007) * CY163841.1 
(A/California/04/2009) * AEE69011.1 
(A/Korea/01-2-2/2009) * CY110891.1 
(A/Netherlands/602/2009) * CY148116.1 
(A/Korea/01-2-9/2009) * CY110906.1 
(A/Mexico/InDRE4487/2009) * GQ303341.1 
(A/Niigata/749/2009) * GU138893.1 
(A/India/P1114854/2011) * KF280666.1 
(A/Cambodia/V1019320/2011) * KC118566.1 
(A/swine/Geldern/IDT2888/04) * EU478821.1 
(A/KOL/507/2007) * AEE68984.1 
(A/swine/Hannover/1/81) * EU478795.1 
(A/swine/Minnesota/SG1403/2011) H1N2 CY159018.1 
(A/swine/Colorado/02875/2009) * CY159450.1 
(A/Singapore/1-MA12E/1957) H2N2 CY087793.1 
(A/Wisconsin/67/2005(H3N2)) H3N2 CY164001.1 
(A/HaNoi/Q769/2007(H3N2)) * CY105751.1 
(A/swine/Quebec/01003/2006(H3N2)) * CY160179.1 
(A/swine/Italy/1553-2/98) * AJ293938.1 
(A/blow fly/Kyoto/93/2004) H5N1 AB212651.2 
(A/chicken/Moscow/2/2007) * EF474449.1 
(A/chicken/Kulon Progo/BBVet-XII-2/2004) * DQ492930.1 
(A/Thailand/2(SP-33)/2004) * AY627893.1 
(A/Viet Nam/1194/2004) * AY651387.1 
(A/Viet Nam/1203/2004) * AAT70528.1 
(A/Hong Kong/156/97) * AAC34266.1 
(A/duck/Yangzhou/013/2008) H6N5 ACZ54004.1 
(A/Chicken/New York/8030-2/96) H7N2 AF073190.1 
(A/Nanjing/2/2013) * KF007047.1 
(A/shearwater/Australia/2/1972) H10N8 CY087761.1 
M2e consensus sequence - (Fiers et al. 2004) 
